Walgreens Boots Alliance (WBA) 10-Q 28 Mar 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page	6 Months Ended
	Feb. 28, 2023 shares
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Feb. 28, 2023
Document Transition Report	false
Entity File Number	001-36759
Entity Registrant Name	WALGREENS BOOTS ALLIANCE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-1758322
Entity Address, Address Line One	108 Wilmot Road
Entity Address, City or Town	Deerfield
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	847
Local Phone Number	315-3700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)	862,795,720
Entity Central Index Key	0001618921
Current Fiscal Year End Date	--08-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false
Common Stock, $0.01 par value
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	WBA
Security Exchange Name	NASDAQ
3.600% Walgreens Boots Alliance, Inc. notes due 2025
Document Information [Line Items]
Title of 12(b) Security	3.600% Walgreens Boots Alliance, Inc. notes due 2025
Trading Symbol	WBA25
Security Exchange Name	NASDAQ
2.125% Walgreens Boots Alliance, Inc notes due 2026
Document Information [Line Items]
Title of 12(b) Security	2.125% Walgreens Boots Alliance, Inc. notes due 2026
Trading Symbol	WBA26
Security Exchange Name	NASDAQ

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions	Feb. 28, 2023	Aug. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,088	$ 1,358
Marketable securities	752	1,114
Accounts receivable, net	5,730	5,017
Inventories	8,757	8,353
Other current assets	1,362	1,059
Total current assets	17,689	16,902
Non-current assets:
Property, plant and equipment, net	11,576	11,729
Operating lease right-of-use assets	22,024	21,259
Goodwill	28,343	22,280
Intangible assets, net	13,864	10,730
Equity method investments (see Note 5)	4,069	5,495
Other non-current assets	2,913	1,730
Total non-current assets	82,790	73,222
Total assets	100,479	90,124
Current liabilities:
Short-term debt	4,222	1,059
Trade accounts payable (see Note 16)	12,720	11,255
Operating lease obligations	2,340	2,286
Accrued expenses and other liabilities	8,822	7,899
Income taxes	124	84
Total current liabilities	28,228	22,583
Non-current liabilities:
Long-term debt	8,820	10,615
Operating lease obligations	22,195	21,517
Deferred income taxes	2,081	1,442
Accrued litigation obligations	6,365	551
Other non-current liabilities	3,193	3,009
Total non-current liabilities	42,654	37,134
Commitments and contingencies (see Note 10)
Total liabilities	70,882	59,717
Redeemable non-controlling interests	158	1,042
Equity:
Preferred stock $.01 par value; authorized 32 million shares, none issued	0	0
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at February 28, 2023 and August 31, 2022	12	12
Paid-in capital	10,629	10,950
Retained earnings	33,952	37,801
Accumulated other comprehensive loss	(2,654)	(2,805)
Treasury stock, at cost; 309,717,898 shares at February 28, 2023 and 307,874,161 shares at August 31, 2022	(20,747)	(20,683)
Total Walgreens Boots Alliance, Inc. shareholders’ equity	21,192	25,275
Non-controlling interests	8,247	4,091
Total equity	29,439	29,366
Total liabilities, redeemable non-controlling interests and equity	$ 100,479	$ 90,124

CONSOLIDATED CONDENSED BALANC_2

CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Feb. 28, 2023	Aug. 31, 2022
Equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	32,000,000	32,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	3,200,000,000	3,200,000,000
Common stock, issued (in shares)	1,172,513,618	1,172,513,618
Treasury stock, at cost (in shares)	309,717,898	307,874,161

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF EQUITY - USD ($) $ in Millions	Total	Common stock	Treasury stock amount	Paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings	Noncontrolling interests
Beginning balance (in shares) at Aug. 31, 2021		865,373,636
Beginning balance at Aug. 31, 2021	$ 23,822	$ 12	$ (20,593)	$ 10,988	$ (2,109)	$ 35,121	$ 402
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	4,370					4,463	(93)
Other comprehensive income, net of tax	(220)				(220)
Dividends declared and distributions	(834)					(828)	(6)
Treasury stock purchases (in shares)		(3,910,000)
Treasury stock purchases	(187)		(187)
Employee stock purchase and option plans (in shares)		2,309,828
Employee stock purchase and option plans	2		68	(66)
Stock-based compensation	115			80			35
Acquisition of non-controlling interests	(55)			62			(116)
Redeemable non-controlling interests redemption price adjustments	(90)			(90)
Business combination	3,944						3,944
Ending balance (in shares) at Feb. 28, 2022		863,773,464
Ending balance at Feb. 28, 2022	30,867	$ 12	(20,712)	10,973	(2,328)	38,757	4,166
Beginning balance (in shares) at Nov. 30, 2021		863,842,376
Beginning balance at Nov. 30, 2021	30,579	$ 12	(20,700)	10,966	(2,301)	38,286	4,316
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	818					883	(65)
Other comprehensive income, net of tax	(24)				(26)		3
Dividends declared and distributions	(419)					(413)	(6)
Treasury stock purchases (in shares)		(730,250)
Treasury stock purchases	(33)		(33)
Employee stock purchase and option plans (in shares)		661,338
Employee stock purchase and option plans	14		21	(7)
Stock-based compensation	79			44			35
Acquisition of non-controlling interests	(55)			62			(116)
Redeemable non-controlling interests redemption price adjustments	(83)			(83)
Non-controlling interests contribution and other	(8)			(8)
Ending balance (in shares) at Feb. 28, 2022		863,773,464
Ending balance at Feb. 28, 2022	30,867	$ 12	(20,712)	10,973	(2,328)	38,757	4,166
Beginning balance (in shares) at Aug. 31, 2022		864,639,457
Beginning balance at Aug. 31, 2022	29,366	$ 12	(20,683)	10,950	(2,805)	37,801	4,091
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	(3,248)					(3,018)	(230)
Other comprehensive income, net of tax	153				151		3
Dividends declared and distributions	(881)					(831)	(50)
Treasury stock purchases (in shares)		(4,438,228)
Treasury stock purchases	(150)		(150)
Employee stock purchase and option plans (in shares)		2,594,491
Employee stock purchase and option plans	22		86	(64)
Stock-based compensation	112			48			64
Acquisition of non-controlling interests	171			171
Business combination	4,325			(43)			4,369
Non-controlling interests contribution and other	(432)			(432)
Ending balance (in shares) at Feb. 28, 2023		862,795,720
Ending balance at Feb. 28, 2023	29,439	$ 12	(20,747)	10,629	(2,654)	33,952	8,247
Beginning balance (in shares) at Nov. 30, 2022		862,342,235
Beginning balance at Nov. 30, 2022	24,582	$ 12	(20,762)	10,477	(2,815)	33,664	4,006
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings (loss)	545					703	(158)
Other comprehensive income, net of tax	164				161		2
Dividends declared and distributions	(422)					(416)	(6)
Employee stock purchase and option plans (in shares)		453,485
Employee stock purchase and option plans	15		15	0
Stock-based compensation	57			23			34
Acquisition of non-controlling interests	171			171
Business combination	4,325			(43)			4,369
Non-controlling interests contribution and other	1			1
Ending balance (in shares) at Feb. 28, 2023		862,795,720
Ending balance at Feb. 28, 2023	$ 29,439	$ 12	$ (20,747)	$ 10,629	$ (2,654)	$ 33,952	$ 8,247

CONSOLIDATED CONDENSED STATEM_2

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Income Statement [Abstract]
Sales	$ 34,862	$ 33,756	$ 68,244	$ 67,656
Cost of sales	27,807	26,047	54,236	52,374
Gross profit	7,055	7,708	14,008	15,283
Selling, general and administrative expenses	6,934	6,565	20,091	12,956
Equity earnings in AmerisourceBergen	75	103	129	202
Operating income (loss)	197	1,246	(5,954)	2,529
Other income (expense), net	552	(198)	1,544	2,418
Earnings (loss) before interest and income tax provision (benefit)	749	1,047	(4,410)	4,947
Interest expense, net	141	100	252	186
Earnings (loss) before income tax provision (benefit)	607	947	(4,662)	4,761
Income tax provision (benefit)	70	172	(1,377)	447
Post-tax earnings from other equity method investments	6	31	13	24
Net earnings (loss)	544	806	(3,272)	4,337
Net loss attributable to non-controlling interests	(159)	(78)	(253)	(126)
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.	703	883	(3,018)	4,463
Net earnings (loss) per common share:
Net earnings (loss) attributable to Walgreens Boots Alliance, Inc.	$ 703	$ 883	$ (3,018)	$ 4,463
Net earnings (loss) per common share:
Basic (in dollars per share)	$ 0.81	$ 1.02	$ (3.50)	$ 5.16
Diluted (in dollars per share)	$ 0.81	$ 1.02	$ (3.50)	$ 5.15
Weighted average common shares outstanding:
Basic (in shares)	862.6	863.5	863.1	864.6
Diluted (in shares)	863.4	865.2	863.1	866.4

CONSOLIDATED CONDENSED STATEM_3

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Net earnings (loss)	$ 544	$ 806	$ (3,272)	$ 4,337
Other comprehensive income (loss), net of tax:
Pension/post-retirement obligations	(5)	(8)	(10)	(13)
Unrealized (loss) gain on cash flow hedges	0	0	(2)	1
Net investment hedges (loss) gain	(43)	(20)	(73)	24
Movement on available for sale debt securities	(1)	0	(1)	(96)
Share of other comprehensive income (loss) of equity method investments	88	(80)	92	(125)
Currency translation adjustments	124	84	147	(10)
Total other comprehensive income (loss)	164	(24)	153	(220)
Total comprehensive income (loss)	707	782	(3,118)	4,117
Comprehensive loss attributable to non-controlling interests	(157)	(75)	(251)	(126)
Comprehensive income (loss) attributable to Walgreens Boots Alliance, Inc.	$ 864	$ 857	$ (2,868)	$ 4,243

CONSOLIDATED CONDENSED STATEM_4

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022
Cash flows from operating activities:
Net earnings (loss)	$ (3,272)	$ 4,337
Adjustments to reconcile net (loss) earnings to net cash provided by operating activities:
Depreciation and amortization	1,055	1,024
Deferred income taxes	(1,600)	94
Stock compensation expense	293	170
Earnings from equity method investments	(143)	(226)
Gain on previously held investment interests	0	(2,576)
Gain on sale of equity method investments	(1,512)	0
Impairment of equity method investments and investments in equity securities	8	190
Other	(383)	(60)
Changes in operating assets and liabilities:
Accounts receivable, net	(221)	495
Inventories	(237)	(803)
Other current assets	(107)	(37)
Trade accounts payable	1,279	46
Accrued expenses and other liabilities	(684)	(476)
Income taxes	92	154
Accrued litigation obligations	6,795	0
Other non-current assets and liabilities	(125)	(147)
Net cash provided by operating activities	1,239	2,184
Cash flows from investing activities:
Additions to property, plant and equipment	(1,108)	(870)
Proceeds from sale-leaseback transactions	942	475
Proceeds from sale of other assets	3,261	33
Business, investment and asset acquisitions, net of cash acquired	(6,813)	(1,918)
Other	134	99
Net cash used for investing activities	(3,583)	(2,181)
Cash flows from financing activities:
Net change in short-term debt with maturities of 3 months or less	1,128	1,289
Proceeds from debt	1,716	9,928
Payments of debt	(1,530)	(7,331)
Acquisition of non-controlling interests	(1,039)	(2,108)
Proceeds from issuance of non-controlling interests	2,523	0
Stock purchases	(150)	(187)
Proceeds related to employee stock plans, net	22	32
Cash dividends paid	(829)	(833)
Other	(75)	(22)
Net cash provided by financing activities	1,766	769
Effect of exchange rate changes on cash, cash equivalents, marketable securities and restricted cash	13	(16)
Changes in cash, cash equivalents, marketable securities and restricted cash:
Net (decrease) increase in cash, cash equivalents, marketable securities and restricted cash	(566)	756
Cash, cash equivalents, marketable securities and restricted cash at beginning of period	2,558	1,270
Cash, cash equivalents, marketable securities and restricted cash at end of period	$ 1,993	$ 2,027

Accounting policies

Accounting policies	6 Months Ended
	Feb. 28, 2023
Accounting Policies [Abstract]
Accounting policies	Accounting policies Basis of presentation The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest and certain variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated. The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2022, as amended by Form 10-K/A for the fiscal year ended August 31, 2022 filed on November 23, 2022. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of opioid-related claims and litigation settlements, COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payor and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years. Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented. Adoption of new accounting pronouncements Disclosures by business entities about government assistance In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The Company adopted the new standard effective September 1, 2022, and the adoption did not impact the Company's disclosures within these consolidated condensed financial statements. New accounting pronouncements not yet adopted Acquired contract assets and contract liabilities in a business combination In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance. Liabilities—Supplier Finance Programs In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Topic 405-50) - Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. This ASU is expected to improve financial reporting by requiring new disclosures about the programs, thereby allowing financial statement users to better consider the effect of the programs on an entity’s working capital, liquidity, and cash flows. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024), except for the amendment on roll forward information which is effective for fiscal years beginning after December 15, 2023 (fiscal 2025). The Company is evaluating the effect of adopting this new accounting guidance.

Acquisitions and other investme

Acquisitions and other investments	6 Months Ended
	Feb. 28, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions and other investments	Acquisitions and other investments Summit acquisition On January 3, 2023, Village Practice Management Company, LLC (“VillageMD”), through its parent company, following an internal reorganization, completed the acquisition of WP CityMD TopCo (“Summit”), a leading provider of primary, specialty and urgent care in exchange, for $7.0 billion aggregate consideration, consisting of $4.85 billion of cash consideration paid, $2.05 billion in preferred units of VillageMD issued to Summit equity holders and $100 million of cash to be paid one year following closing. The cash consideration includes $86 million of cash paid to fund acquisition-related bonuses to Summit Health-CityMD employees which is recognized as compensation expense of the Company. In addition, VillageMD paid off approximately $1.9 billion in net debt of Summit. In connection with the amended Agreement and Plan of Merger, and in order to finance the acquisition, the Company and Cigna Health & Life Insurance Company (“Cigna”) acquired preferred units of VillageMD in exchange for $1.75 billion and $2.5 billion in aggregate consideration, respectively. Following the Summit acquisition, the Company remains the largest and consolidating equity holder of VillageMD with ownership of approximately 53% of the outstanding equity interests on a fully diluted basis. Further, the Company entered into a credit agreement with VillageMD pursuant to which the Company provided VillageMD senior secured credit facilities in the aggregate amount of $2.25 billion, consisting of (i) a senior secured term loan facility in an aggregate original principal amount of $1.75 billion to support the acquisition of Summit; and (ii) a senior secured revolving credit facility in an aggregate original committed amount of $500 million available for general corporate purposes. In connection with the issuance of the senior secured credit facilities, the Company received a $220 million credit for certain fees payable by VillageMD in the form of preferred units of VillageMD. The intercompany senior secured credit facilities will eliminate in consolidation. The Company accounted for this acquisition as a business combination resulting in consolidation of Summit within the U.S. Healthcare segment in its financial statements. As of February 28, 2023, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired and liabilities assumed. As such, the preliminary purchase price allocation will be subject to further refinement and may change. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified and liabilities assumed. The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Cash consideration 1 $ 4,790 Deferred consideration 100 Summit debt paid at closing 1,963 Fair value of equity consideration 1,980 Total $ 8,833 Identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 75 Accounts receivable, net 361 Property, plant and equipment 593 Intangible assets 2 3,359 Operating lease right-of-use assets 757 Other assets 192 Operating lease obligations (773) Deferred tax liability (918) Other liabilities (507) Total identifiable net assets $ 3,139 Goodwill $ 5,693 1. Cash considerations excludes $86 million of cash paid to fund acquisition-related bonuses to Summit employees which is recognized as compensation expense of the Company. 2. Intangibles acquired include provider networks and trade names with fair values of $1.9 billion and $1.5 billion, respectively. Estimated useful lives are 16 years and 11 to 15 years, respectively. The goodwill represents anticipated future growth and expansion opportunities into new healthcare offerings and new markets. Supplemental pro forma information - Summit The following table represents unaudited supplemental pro forma consolidated sales for the three and six months ended February 28, 2023 and 2022, as if the acquisition of Summit had occurred at the beginning of each period. The unaudited pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company's results would have been had the acquisition occurred at the beginning of each period presented or results which may occur in the future. Three months ended February 28, Six months ended February 28, (Unaudited, in millions) 2023 2022 2023 2022 Sales $ 35,119 $ 34,402 $ 69,216 $ 68,924 Actual sales of Summit, from the acquisition date, for the three and six months ended February 28, 2023, included in the Consolidated Condensed Statements of Earnings are as follows: Three and six months ended February 28, (in millions) 2023 Sales $ 463 Pro forma net earnings of the Company, assuming the acquisition had occurred at the beginning of each period presented, would not be materially different from the results reported. VillageMD acquisition On November 24, 2021, the Company completed the acquisition of VillageMD, national provider of value-based primary care services. Pursuant to the terms and subject to the conditions set forth in the Unit Purchase Agreement, the Company purchased additional outstanding equity interests of VillageMD, increasing the Company’s total beneficial ownership in VillageMD’s outstanding equity interests from approximately 30% to approximately 63%, on a fully diluted basis, for a purchase price of $5.2 billion. The total purchase price was comprised of cash consideration of $4.0 billion and a promissory note of $1.2 billion. The cash consideration of $4.0 billion consisted of $2.9 billion paid to existing shareholders, including $1.9 billion paid to existing shareholders as part of the fully subscribed tender offer concluded on December 28, 2021, and $1.1 billion paid in exchange for new preferred units issued by VillageMD. Subject to notice being served, the Company had an option to prepay, and VillageMD had an option to require redemption of, the promissory note at any time. The promissory note was eliminated in consolidation within the Consolidated Condensed Balance Sheet as of August 31, 2022. The promissory note was paid in January 2023 prior to the Summit acquisition. The Company accounted for this acquisition as a business combination resulting in consolidation of VillageMD within the U.S. Healthcare segment in its financial statements. A non-controlling interest was recognized at fair value. As a result of this acquisition, in the three months ended November 30, 2021, the Company recognized a pre-tax gain in Other income (expense), net in the Consolidated Condensed Statements of Earnings of $1,597 million related to the fair valuation of the Company’s previously held minority equity interest. The Company also recorded a pre-tax gain of $577 million in Other income (expense), net in the Consolidated Condensed Statements of Earnings related to the conversion to equity of the Company’s previously held investment in convertible debt securities of VillageMD, reclassified from within Accumulated other comprehensive loss in the Consolidated Condensed Balance Sheets. A majority of the gains did not generate a tax expense. In the three months ended November 30, 2022, the Company completed the purchase price allocation and recorded certain deferred income tax related measurement period adjustments based on additional information, resulting in an increase to goodwill of $125 million. The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Total purchase price $ 5,200 Less: purchase price for issuance of new preferred units at fair value 1 (2,300) Net consideration 2,900 Fair value of share-based compensation awards attributable to pre-combination services 2 683 Fair value of previously held equity and debt 3,211 Fair value of non-controlling interests 3,257 Total $ 10,051 Identifiable assets acquired and liabilities assumed: Tangible assets 1 $ 634 Intangible assets 3 1,621 Liabilities (370) Total identifiable net assets $ 1,885 Goodwill $ 8,166 1. Comprised of cash consideration of $1.1 billion and a promissory note of $1.2 billion. This consideration was provided in exchange for the issuance of new preferred units by VillageMD. VillageMD’s tangible assets acquired exclude this $1.1 billion of cash and $1.2 billion promissory note receivable. 2. Primarily related to vested share-based compensation awards. 3. Intangibles acquired include primary care provider network, trade names and developed technology, with a fair value of $1.2 billion, $295 million and $76 million, respectively. Estimated useful lives are 15, 13 and 5 years, respectively. The goodwill represents anticipated future growth and expansion opportunities into new markets. Shields acquisition On October 29, 2021, the Company completed the acquisition of Shields Health Solutions Parent, LLC (“Shields”), a specialty pharmacy integrator and accelerator for hospitals. Pursuant to the terms and subject to the conditions set forth in the Securities Purchase Agreement, the Company purchased additional outstanding equity interests of Shields, increasing the Company’s total beneficial ownership in Shields’ outstanding equity interests from 25% to approximately 70%, for cash consideration of $969 million. The Company accounted for this acquisition as a business combination resulting in consolidation of Shields within the U.S. Healthcare segment in its financial statements. A non-controlling interest was recognized at fair value. Under the terms of the transaction agreements, the Company had an option to acquire the remaining equity interests of Shields in the future. Shields’ other equity holders also had an option to require the Company to purchase the remaining equity interests. Considering the contractual terms related to the non-controlling interests, it was classified as redeemable non-controlling interests in the Consolidated Condensed Balance Sheets upon acquisition. As a result of this acquisition, in the three months ended November 30, 2021, the Company remeasured its previously held minority equity interest in Shields at fair value resulting in a pre-tax gain of $402 million recognized in Other income (expense), net in the Consolidated Condensed Statements of Earnings. A majority of the gain did not generate a tax expense. In the three months ended November 30, 2022, the Company completed the purchase price allocation and recorded certain deferred income tax related measurement period adjustments based on additional information, resulting in an increase to goodwill of $72 million. The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Cash consideration $ 969 Fair value of share-based compensation awards attributable to pre-combination services 13 Fair value of previously held equity interests 502 Fair value of non-controlling interests 589 Total $ 2,074 Identifiable assets acquired and liabilities assumed: Tangible assets $ 84 Intangible assets 1 1,060 Liabilities (600) Total identifiable net assets $ 544 Goodwill $ 1,529 1. Intangibles acquired include customer relationships, trade names and developed technology, with a fair value of $896 million, $47 million and $117 million, respectively. Estimated useful lives are 13, 13 and 5 years, respectively. The goodwill represents anticipated future growth and expansion opportunities into new healthcare offerings. On December 28, 2022 the Company acquired the remaining 30% equity interest in Shields for $1.4 billion of cash consideration. CareCentrix acquisition On August 31, 2022, the Company completed the acquisition of CCX Next, LLC (“CareCentrix”). Pursuant to the terms and subject to the conditions set forth in the Membership Interest Purchase Agreement, the Company acquired approximately 55% controlling equity interest in CareCentrix, a leading player in the post-acute and home care management sectors, for cash consideration of $339 million. The cash consideration includes $12 million paid to employees, which was recognized as compensation expense by the Company. The Company accounted for this acquisition as a business combination resulting in consolidation of CareCentrix within the U.S. Healthcare segment in its financial statements. A non-controlling interest was recognized at fair value. Under the terms of the transaction agreements, the Company had an option to acquire the remaining equity interests of CareCentrix in the future. CareCentrix’s other equity holders also had an option to require the Company to purchase the remaining equity interests. Considering the contractual terms related to the non-controlling interests, it was classified as redeemable non-controlling interests in the Consolidated Condensed Balance Sheets. In the three and six months ended February 28, 2023, the Company recorded certain measurement period adjustments based on additional information, primarily related to acquired intangible assets and certain liabilities assumed, resulting in a decrease to goodwill of $6 million and an increase to goodwill of $56 million, respectively. As of February 28, 2023, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired and liabilities assumed. As such, the preliminary purchase price allocation will be subject to further refinement and may change. These changes may relate to finalization of the fair value of the purchase consideration and the allocation of purchase consideration to all tangible and intangible assets acquired and identified and liabilities assumed. The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Cash consideration 1 $ 327 Contingent consideration 4 Fair value of share-based compensation awards attributable to pre-combination services 66 Fair value of non-controlling interests 217 Total $ 614 Identifiable assets acquired and liabilities assumed: Tangible assets $ 358 Intangible assets 2 426 Liabilities (680) Total identifiable net assets $ 104 Goodwill $ 509 1. Excludes $12 million of cash paid to employees, which was recognized as compensation expense by the Company. 2. Intangibles acquired include customer relationships, trade names and developed technology, with a fair value of $247 million, $93 million and $86 million, respectively. Estimated useful lives are 13, 13 and 5 years, respectively. The goodwill represents anticipated future growth and expansion opportunities into new healthcare offerings. On October 11, 2022, the Company entered into a definitive agreement to acquire the remaining 45% equity interest of CareCentrix for approximately $392 million of cash consideration, less transaction expenses. As a result, as of November 30, 2022, the redeemable non-controlling interest to be acquired was reclassified to Accrued expenses and other liabilities in the Consolidated Condensed Balance Sheets. The acquisition is expected to close in the third quarter of fiscal 2023. Supplemental pro forma information - VillageMD, Shields and CareCentrix The following table represents unaudited supplemental pro forma consolidated sales for the three and six months ended February 28, 2022, as if the acquisitions of VillageMD, Shields and CareCentrix had occurred at the beginning of each period. The unaudited pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company's results would have been had the acquisitions occurred at the beginning of each period presented or results which may occur in the future. Three months ended February 28, Six months ended February 28, (Unaudited, in millions) 2022 2022 Sales $ 34,063 $ 68,627 Actual sales of the acquired companies for the three and six months ended February 28, 2022, included in the Consolidated Condensed Statements of Earnings are as follows: Three months ended February 28, Six months ended February 28, (in millions) 2022 2022 Sales $ 527 $ 577 Pro forma net earnings of the Company, assuming the acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported. Other acquisitions and investments The Company acquired certain prescription files and related pharmacy inventory primarily in the United States (“U.S.”) for the aggregate purchase price of $35 million and $90 million during the three and six months ended February 28, 2023, respectively, and $42 million and $116 million during the three and six months ended February 28, 2022, respectively.

Exit and disposal activities

Exit and disposal activities	6 Months Ended
	Feb. 28, 2023
Restructuring and Related Activities [Abstract]
Exit and disposal activities	Exit and disposal activities Transformational Cost Management Program On December 20, 2018, the Company announced a transformational cost management program that was expected to deliver in excess of $2.0 billion of annual cost savings by fiscal 2022 (the “Transformational Cost Management Program”). The Company achieved this goal at the end of fiscal 2021. On October 12, 2021, the Company expanded and extended the Transformational Cost Management Program through the end of fiscal 2024 and increased its annual cost savings target to $3.3 billion by the end of fiscal 2024. In fiscal 2022, the Company increased its annual cost savings target from $3.3 billion to $3.5 billion, by the end of fiscal 2024. The Company is currently on track to achieve the savings target. The Transformational Cost Management Program, which is multi-faceted and includes divisional optimization initiatives, global smart spending, global smart organization and the transformation of the Company’s information technology (IT) capabilities, is designed to help the Company achieve increased cost efficiencies. To date, the Company has taken actions across all aspects of the Transformational Cost Management Program which focus on the U.S. Retail Pharmacy and International reportable segments along with the Company's global functions. Divisional optimization within the Company’s segments includes activities such as optimization of stores, including plans to close approximately 350 Boots stores in the United Kingdom (“UK”) and approximately 450 to 500 stores in the U.S. As of February 28, 2023, the Company has closed 252 and 403 stores in the UK and U.S., respectively. The Company currently estimates that the Transformational Cost Management Program will result in cumulative pre-tax charges to its GAAP financial results of approximately $3.6 billion to $3.9 billion, of which $3.3 billion to $3.6 billion are expected to be recorded as exit and disposal activities. In addition to the impacts discussed above, as a result of the actions related to store closures taken under the Transformational Cost Management Program, the Company recorded $508 million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard (Topic 842) that became effective on September 1, 2019. From the inception of the Transformational Cost Management Program to February 28, 2023, the Company has recognized cumulative pre-tax charges to its financial results in accordance with GAAP of $2.2 billion, which were primarily recorded within Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. These charges included $700 million related to lease obligations and other real estate costs, $556 million in asset impairments, $754 million in employee severance and business transition costs and $228 million of information technology transformation and other exit costs. Costs related to exit and disposal activities under the Transformational Cost Management Program for the three and six months ended February 28, 2023 and 2022, respectively, were as follows (in millions): Three months ended February 28, 2023 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 20 $ — $ — $ 20 Asset impairments 96 (1) — 95 Employee severance and business transition costs 11 1 3 15 Information technology transformation and other exit costs 4 5 (1) 9 Total exit and disposal charges $ 131 $ 4 $ 2 $ 138 Six months ended February 28, 2023 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 98 $ — $ — $ 98 Asset impairments 115 (1) — 113 Employee severance and business transition costs 22 2 7 31 Information technology transformation and other exit costs 16 10 (1) 25 Total exit and disposal charges $ 250 $ 10 $ 6 $ 267 Three months ended February 28, 2022 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 5 $ 1 $ — $ 5 Asset impairments 1 3 — 4 Employee severance and business transition costs 36 — 5 41 Information technology transformation and other exit costs 1 4 — 5 Total exit and disposal charges $ 43 $ 8 $ 5 $ 56 Six months ended February 28, 2022 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 91 $ 3 $ — $ 95 Asset impairments 16 28 — 44 Employee severance and business transition costs 56 9 14 79 Information technology transformation and other exit costs 2 11 — 13 Total exit and disposal charges $ 166 $ 51 $ 14 $ 231 The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions): Lease obligations and other real estate costs Asset Impairments Employee severance and business transition costs Information technology transformation and other exit costs Total Balance at August 31, 2022 $ 10 $ — $ 76 $ 27 $ 113 Costs 98 113 31 25 267 Payments (51) — (72) (17) (139) Other (57) (113) 1 — (170) Balance at February 28, 2023 $ — $ — $ 36 $ 36 $ 72

Leases

Leases	6 Months Ended
	Feb. 28, 2023
Leases [Abstract]
Leases	LeasesThe Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. Lease commencement is the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight line basis over the lease term. In addition to minimum fixed rentals, some leases provide for contingent rentals based on sales volume. Supplemental balance sheet information related to leases were as follows (in millions): Balance Sheet supplemental information: February 28, 2023 August 31, 2022 Operating leases: Operating lease right-of-use assets $ 22,024 $ 21,259 Operating lease obligations - current 2,340 2,286 Operating lease obligations - non-current 22,195 21,517 Total operating lease obligations $ 24,534 $ 23,803 Finance leases: Right-of-use assets included in: Property, plant and equipment, net $ 694 $ 645 Lease obligations included in: Accrued expenses and other liabilities 53 37 Other non-current liabilities 931 899 Total finance lease obligations $ 984 $ 936 Supplemental income statement information related to leases were as follows (in millions): Three months ended February 28, Six months ended February 28, Statement of Earnings supplemental information: 2023 2022 2023 2022 Operating lease cost Fixed $ 853 $ 815 $ 1,667 $ 1,619 Variable 1 203 197 395 402 Finance lease cost Amortization $ 11 $ 11 $ 21 $ 22 Interest 12 13 24 26 Sublease income $ 28 $ 26 $ 57 $ 51 Impairment of right-of-use assets 4 3 71 71 Gain on sale and leaseback 2 U.S. Retail Pharmacy $ 211 $ 148 $ 384 $ 235 International 3 132 — 148 — Total gain on sale and leaseback 2 $ 343 $ 148 $ 532 $ 235 1 Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume. 2 Recorded within Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. 3 Includes gain on sale and leaseback related to Germany wholesale business of $132 million and $148 million for the three and six months ended February 2023, respectively, of which $24 million and $41 million related to the optimization of warehouse locations as part of acquisition integration activities. Six months ended February 28, Other supplemental information: 2023 2022 Cash paid for amounts included in the measurement of lease obligations Operating cash flows from operating leases $ 1,720 $ 1,666 Operating cash flows from finance leases 22 23 Financing cash flows from finance leases 21 21 Total $ 1,763 $ 1,710 Right-of-use assets obtained in exchange for new lease obligations Operating leases $ 1,135 $ 1,005 Finance leases 18 11 Total $ 1,154 $ 1,016 Weighted average lease term and discount rate for real estate leases were as follows: Weighted average lease terms and discount rates: February 28, 2023 August 31, 2022 Weighted average remaining lease term in years Operating leases 9.8 10.0 Finance leases 17.7 19.0 Weighted average discount rate Operating leases 5.26 % 4.83 % Finance leases 5.26 % 5.19 % The aggregate future lease payments for operating and finance leases as of February 28, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2023 (Remaining period) $ 53 $ 1,805 2024 105 3,555 2025 101 3,450 2026 98 3,361 2027 97 3,266 2028 88 3,108 Later 958 12,980 Total undiscounted minimum lease payments $ 1,501 $ 31,524 Less: Present value discount 516 6,990 Lease liability $ 984 $ 24,534 1. Total undiscounted minimum lease payments include approximately $3.5 billion of payments related to optional renewal periods that have not been contractually exercised, but are reasonably certain of being exercised. 2. Total undiscounted minimum lease payments exclude sublease rental income of approximately $600 million due to the Company under non-cancelable sublease terms.
Leases	LeasesThe Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. Lease commencement is the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight line basis over the lease term. In addition to minimum fixed rentals, some leases provide for contingent rentals based on sales volume. Supplemental balance sheet information related to leases were as follows (in millions): Balance Sheet supplemental information: February 28, 2023 August 31, 2022 Operating leases: Operating lease right-of-use assets $ 22,024 $ 21,259 Operating lease obligations - current 2,340 2,286 Operating lease obligations - non-current 22,195 21,517 Total operating lease obligations $ 24,534 $ 23,803 Finance leases: Right-of-use assets included in: Property, plant and equipment, net $ 694 $ 645 Lease obligations included in: Accrued expenses and other liabilities 53 37 Other non-current liabilities 931 899 Total finance lease obligations $ 984 $ 936 Supplemental income statement information related to leases were as follows (in millions): Three months ended February 28, Six months ended February 28, Statement of Earnings supplemental information: 2023 2022 2023 2022 Operating lease cost Fixed $ 853 $ 815 $ 1,667 $ 1,619 Variable 1 203 197 395 402 Finance lease cost Amortization $ 11 $ 11 $ 21 $ 22 Interest 12 13 24 26 Sublease income $ 28 $ 26 $ 57 $ 51 Impairment of right-of-use assets 4 3 71 71 Gain on sale and leaseback 2 U.S. Retail Pharmacy $ 211 $ 148 $ 384 $ 235 International 3 132 — 148 — Total gain on sale and leaseback 2 $ 343 $ 148 $ 532 $ 235 1 Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume. 2 Recorded within Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. 3 Includes gain on sale and leaseback related to Germany wholesale business of $132 million and $148 million for the three and six months ended February 2023, respectively, of which $24 million and $41 million related to the optimization of warehouse locations as part of acquisition integration activities. Six months ended February 28, Other supplemental information: 2023 2022 Cash paid for amounts included in the measurement of lease obligations Operating cash flows from operating leases $ 1,720 $ 1,666 Operating cash flows from finance leases 22 23 Financing cash flows from finance leases 21 21 Total $ 1,763 $ 1,710 Right-of-use assets obtained in exchange for new lease obligations Operating leases $ 1,135 $ 1,005 Finance leases 18 11 Total $ 1,154 $ 1,016 Weighted average lease term and discount rate for real estate leases were as follows: Weighted average lease terms and discount rates: February 28, 2023 August 31, 2022 Weighted average remaining lease term in years Operating leases 9.8 10.0 Finance leases 17.7 19.0 Weighted average discount rate Operating leases 5.26 % 4.83 % Finance leases 5.26 % 5.19 % The aggregate future lease payments for operating and finance leases as of February 28, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2023 (Remaining period) $ 53 $ 1,805 2024 105 3,555 2025 101 3,450 2026 98 3,361 2027 97 3,266 2028 88 3,108 Later 958 12,980 Total undiscounted minimum lease payments $ 1,501 $ 31,524 Less: Present value discount 516 6,990 Lease liability $ 984 $ 24,534 1. Total undiscounted minimum lease payments include approximately $3.5 billion of payments related to optional renewal periods that have not been contractually exercised, but are reasonably certain of being exercised. 2. Total undiscounted minimum lease payments exclude sublease rental income of approximately $600 million due to the Company under non-cancelable sublease terms.

Equity method investments

Equity method investments	6 Months Ended
	Feb. 28, 2023
Equity Method Investments and Joint Ventures [Abstract]
Equity method investments	Equity method investments Equity method investments were as follows (in millions, except percentages): February 28, 2023 August 31, 2022 Carrying value Ownership percentage Carrying value Ownership percentage AmerisourceBergen $ 2,563 17% $ 3,916 25% Others 1,506 4% - 50% 1,579 8% - 50% Total $ 4,069 $ 5,495 AmerisourceBergen investment As of February 28, 2023 and August 31, 2022, the Company owned 33.7 million and 52.9 million shares of AmerisourceBergen Corporation (“AmerisourceBergen”) common stock, respectively, representing approximately 16.7% and 25.4% of its outstanding common stock based on the share count publicly reported by AmerisourceBergen in its filings with the SEC. On November 10, 2022, the Company sold 13.2 million shares of AmerisourceBergen common stock through a registered public offering and a concurrent share repurchase by AmerisourceBergen for total consideration of approximately $2.0 billion. The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings attributable to the Company’s investment being classified within the operating income of its U.S. Retail Pharmacy segment. Due to the timing and availability of financial information of AmerisourceBergen, the Company accounts for this equity method investment on a financial reporting lag of two months. The Level 1 fair market value of the Company’s equity investment in AmerisourceBergen common stock at February 28, 2023 and August 31, 2022 was $5.2 billion and $7.7 billion, respectively. As of February 28, 2023 the carrying value of the Company’s investment in AmerisourceBergen exceeded its proportionate share of the net assets of AmerisourceBergen by $2.6 billion. This premium of $2.6 billion was recognized as part of the carrying value in the Company’s equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets. Other investments The Company’s other equity method investments primarily include its U.S. investments in Option Care Health, through its subsidiary HC Group Holdings I, LLC, and BrightSpring Health Services, and the Company’s investments in China in Sinopharm Medicine Holding Guoda Drugstores Co., Ltd and Nanjing Pharmaceutical Company Limited. On December 15, 2022, the Company sold its ownership interest in Guangzhou Pharmaceuticals Corporation for total consideration of approximately $150 million.

Goodwill and other intangible a

Goodwill and other intangible assets	6 Months Ended
	Feb. 28, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets Goodwill and indefinite-lived intangible assets are evaluated for impairment annually during the fourth quarter, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit or intangible asset below its carrying value. Based on the analysis completed during fiscal 2022, as of the June 1, 2022 valuation date, the fair values of the Company’s reporting units exceeded their carrying amounts ranging from approximately 7% to approximately 198%. The Boots reporting unit's fair value was in excess of its carrying value by approximately 7%, compared to 18% as of June 1, 2021. As of February 28, 2023 and August 31, 2022, the carrying value of goodwill within the Boots reporting unit was $940 million and $906 million, respectively. The fair values of indefinite-lived intangibles within the Boots reporting unit approximate their carrying values. As of February 28, 2023 and August 31, 2022, the carrying value of the indefinite-lived intangibles within the Boots reporting unit was $5.6 billion and $5.5 billion, respectively. Indefinite-lived intangible assets fair values are estimated using the relief from royalty method and excess earnings method of the income approach. The determination of the fair value of the reporting units requires the Company to make significant estimates and assumptions with respect to the business and financial performance of the Company’s reporting units. Although the Company believes its estimates of fair value are reasonable, actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions, could have a significant impact on either the fair value of the reporting units and indefinite-lived intangibles, the amount of any goodwill and indefinite-lived intangible impairment charges, or both. These estimates can be affected by a number of factors including, but not limited to, the impact of COVID-19, its severity, duration and its impact on global economies, general economic conditions, as well as our profitability. The Company will continue to monitor these potential impacts and economic, industry and market trends, and the impact these may have on the reporting units. Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions): Goodwill roll forward: U.S. Retail Pharmacy International U.S. Healthcare Walgreens Boots Alliance, Inc. August 31, 2022 $ 10,947 $ 1,293 $ 10,040 $ 22,280 Acquisitions — — 5,735 5,735 Adjustments 1 — — 252 252 Currency translation adjustments — 76 — 76 February 28, 2023 $ 10,947 $ 1,369 $ 16,027 $ 28,343 1 Includes measurement period adjustments related to acquisition of VillageMD, Shields and CareCentrix. See Note 2. Acquisitions and other investments for further information. The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): Intangible assets: February 28, 2023 August 31, 2022 Gross amortizable intangible assets Customer relationships and loyalty card holders 1 $ 4,466 $ 4,619 Provider networks 3,099 1,247 Trade names and trademarks 2,271 760 Developed technology 442 436 Others 95 93 Total gross amortizable intangible assets $ 10,373 $ 7,155 Accumulated amortization Customer relationships and loyalty card holders 1 $ 1,574 $ 1,548 Provider networks 126 64 Trade names and trademarks 301 246 Developed technology 92 56 Others 43 39 Total accumulated amortization 2,136 1,953 Total amortizable intangible assets, net $ 8,237 $ 5,202 Indefinite-lived intangible assets Trade names and trademarks $ 4,397 $ 4,319 Pharmacy licenses 1,231 1,209 Total indefinite-lived intangible assets $ 5,628 $ 5,528 Total intangible assets, net $ 13,864 $ 10,730 1 Includes purchased prescription files. Amortization expense for intangible assets was $199 million and $357 million for the three and six months ended February 28, 2023, respectively and $175 million and $340 million for the three and six months ended February 28, 2022, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at February 28, 2023 is as follows (in millions): 2023 (Remaining period) 2024 2025 2026 2027 2028 Estimated annual amortization expense $ 431 $ 846 $ 814 $ 796 $ 733 $ 674

Debt

Debt	6 Months Ended
	Feb. 28, 2023
Debt Disclosure [Abstract]
Debt	Debt Debt carrying values are presented net of unamortized discount and debt issuance costs, where applicable, and foreign currency denominated debt is translated using the spot rates as of the balance sheet date. Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): February 28, 2023 August 31, 2022 Short-term debt Commercial paper 1 $ 1,296 $ — Credit facilities 1 Unsecured 364-day credit facility due 2023 — 1,000 Unsecured two 1,999 — $850 million note issuance 1 0.9500% unsecured notes due 2023 849 — Other 2 79 59 Total short-term debt $ 4,222 $ 1,059 Long-term debt Credit facilities 1 Unsecured two $ — $ 1,998 Unsecured three 999 999 Unsecured three 999 — $850 million note issuance 1 0.9500% unsecured notes due 2023 — 848 $1.5 billion note issuance 1 3.200% unsecured notes due 2030 498 498 4.100% unsecured notes due 2050 792 792 $6 billion note issuance 1 3.450% unsecured notes due 2026 1,443 1,443 4.650% unsecured notes due 2046 318 318 $8 billion note issuance 1 3.800% unsecured notes due 2024 1,155 1,155 4.500% unsecured notes due 2034 301 301 4.800% unsecured notes due 2044 869 869 £700 million note issuance 1 3.600% unsecured pound sterling notes due 2025 361 354 €750 million note issuance 1 2.125% unsecured euro notes due 2026 799 752 $4 billion note issuance 3 4.400% unsecured notes due 2042 263 263 Other 2 23 26 Total long-term debt, less current portion $ 8,820 $ 10,615 1 Notes, borrowings under credit facilities and commercial paper are unsecured and unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding. 2 Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. 3 Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company. $850 million Note Issuance On November 17, 2021, the Company issued, in an underwritten public offering, $850 million of 0.95% Notes due 2023. The Notes contain a call option which allow for the Notes to be repaid, in full or in part, at 100% of the principal amount of the Notes to be redeemed, in each case plus accrued and unpaid interest. Credit facilities December 2022 On December 19, 2022, the Company entered into a $1.0 billion senior unsecured delayed draw term loan credit agreement (the “December 2022 DDTL”). Borrowings under the December 2022 DDTL bear interest at a fluctuating rate per annum equal to, at the Company’s option, the alternate base rate, the term Secured Overnight Financing Rate (“SOFR”) or the daily SOFR, in each case, plus an applicable margin. The applicable margin is in each case based on the rating of the Company’s corporate debt obligations as determined by Moody’s or S&P. The December 2022 DDTL was drawn for the purpose of funding the consideration due for the purchase of Summit and paying fees and expenses related to it. The December 2022 DDTL matures on January 3, 2026. As of February 28, 2023, there were $1.0 billion in borrowings outstanding under the December 2022 DDTL. Amounts borrowed under the December 2022 DDTL and repaid or prepaid may not be reborrowed. June 17, 2022, Revolving Credit Agreements On June 17, 2022, the Company entered into a $3.5 billion unsecured five-year revolving credit facility and a $1.5 billion unsecured 18-month revolving credit facility, with designated borrowers from time to time party thereto and lenders from time to time party thereto (the “2022 Revolving Credit Agreements”). Interest on borrowings under the revolving credit facilities accrues at applicable margins based on the Company's Index Debt Rating and ranges from 80 basis points to 150 basis points over specified benchmark rates for eurocurrency rate and SOFR loans, as applicable. Additionally, the Company pays commitment fees to maintain the availability under the revolving credit facility at applicable fee rates based upon certain criteria at an annual rate on the unutilized portion of the total credit commitment. The five-year facility’s termination date is June 17, 2027, or earlier, subject to the Company's discretion to terminate the agreement. The 18-month facility’s termination date is December 15, 2023, or earlier, subject to the Company's discretion to terminate the agreement. As of February 28, 2023, there were no borrowings outstanding under the 2022 Revolving Credit Agreements. November 2021 Delayed Draw Term Loan On November 15, 2021, the Company entered into a $5.0 billion senior unsecured multi-tranche delayed draw term loan credit facility, (the “November 2021 DDTL”) consisting of (i) a 364-day senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the “364-day loan”), (ii) a two-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the “two-year loan”) and (iii) a three-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $1.0 billion (the “three-year loan”). An aggregate amount of $3.0 billion or more of the November 2021 DDTL was drawn for the purpose of funding the consideration due for the purchase of the increased equity interest in VillageMD, and paying fees and expenses related to the foregoing, and the remainder can be used for general corporate purposes. The maturity dates on the 364 days loan, the two-year loan and the three-year loan are February 15, 2023, November 24, 2023 and November 24, 2024, respectively. On February 14, 2023, the Company repaid the 364 days loan. As of February 28, 2023, there were $3.0 billion in borrowings outstanding under the November 2021 DDTL. Amounts borrowed under the November 2021 DDTL and repaid or prepaid may not be reborrowed. Borrowings under the November 2021 DDTL bear interest at a fluctuating rate per annum equal to, at the Company’s option, the alternate base rate, eurocurrency rate or, from and after the date that daily SOFR becomes available, the daily SOFR, plus an applicable margin. For the 364-day tranche, the applicable margin was approximately 0.75%. For the 2-year and 3-year tranche, the applicable margin is 0.85% and 1.00%, respectively. Debt covenants Each of the Company’s credit facilities described above contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, subject to increase in certain circumstances set forth in the applicable credit agreement. The credit facilities contain various other customary covenants. As of February 28, 2023, the Company was in compliance with all such applicable covenants. Commercial paper The Company periodically borrows under its commercial paper program and may borrow under it in future periods. The Company had average daily commercial paper outstanding of $1.0 billion and $1.1 billion at a weighted average interest rate of 5.04% and 0.33% for the six months ended February 28, 2023 and 2022, respectively. Interest Interest paid by the Company was $288 million and $211 million for the six months ended February 28, 2023 and 2022, respectively.

Financial instruments

Financial instruments	6 Months Ended
	Feb. 28, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Financial instruments The Company uses derivative instruments to hedge its exposure to market risks, including interest rate and currency risks, arising from operating and financing risks. The Company has non-U.S. dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk. The notional amounts and fair value of derivative instruments outstanding were as follows (in millions): February 28, 2023 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 319 $ 6 Other current assets Cross currency interest rate swaps 100 3 Other current assets Cross currency interest rate swaps 650 55 Other non-current assets Foreign currency forwards 8 — Other non-current assets Foreign currency forwards 470 4 Other current liabilities Foreign currency forwards 4 — Other non-current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 1,831 $ 20 Other current assets Foreign currency forwards 2,065 48 Other current liabilities Total return swap 217 8 Other current liabilities August 31, 2022 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 448 $ 19 Other current assets Cross currency interest rate swaps 150 12 Other current assets Cross currency interest rate swaps 750 83 Other non-current assets Foreign currency forwards 3 — Other non-current assets Foreign currency forwards 221 1 Other current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 2,874 $ 49 Other current assets Foreign currency forwards 1,098 6 Other current liabilities Total return swap 183 6 Other current liabilities Net investment hedges The Company uses cross currency interest rate swaps and foreign currency forward contracts to hedge net investments in subsidiaries with non-U.S. dollar functional currencies. For qualifying net investment hedges, changes in the fair value of the derivatives are recorded in Currency translation adjustments within Accumulated other comprehensive loss in the Consolidated Condensed Balance Sheets. Cash flow hedges The Company may use foreign currency forwards and interest rate swaps to hedge the variability in forecasted transactions and cash flows of certain floating-rate debt. For qualifying cash flow hedges, changes in the fair value of the derivatives are recorded in Unrealized gain (loss) on cash flow hedges within Accumulated other comprehensive loss in the Consolidated Condensed Balance Sheets, and released to the Consolidated Condensed Statements of Earnings when the hedged cash flows affect earnings. Derivatives not designated as hedges The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of foreign currency risks. The Company also utilizes total return swaps to economically hedge variability in compensation charges related to certain deferred compensation obligations. The income (expenses) due to changes in fair value of the derivative instruments were recognized in Consolidated Condensed Statements of Earnings as follows (in millions): Three months ended February 28, Six months ended February 28, Location in Consolidated Condensed Statements of Earnings 2023 2022 2023 2022 Foreign currency forwards Selling, general and administrative expenses 1 $ — $ (51) $ — $ 4 Total return swap Selling, general and administrative expenses (3) (8) — (10) Foreign currency forwards Other income (expense), net 1,2 (73) — (92) (1) 1. In fiscal 2023, certain expenses related to derivative instruments used as economic hedges, were presented as Other income (expense), net within the Consolidated Condensed Statements of Earnings, whereas these expenses were recorded within Selling, general, and administrative expenses within the Consolidated Condensed Statements of Earnings in prior periods. 2. Excludes remeasurement gains and losses on economically hedged assets and liabilities. Derivatives credit risk Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty. Derivatives offsetting The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.

Fair value measurements

Fair value measurements	6 Months Ended
	Feb. 28, 2023
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements The Company measures certain assets and liabilities in accordance with Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels: Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Observable inputs other than quoted prices in active markets. Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Assets and liabilities measured at fair value on a recurring basis were as follows (in millions): February 28, 2023 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 752 $ 752 $ — $ — Cross currency interest rate swaps 2 58 — 58 — Foreign currency forwards 3 27 — 27 — Liabilities : Foreign currency forwards 3 $ 52 $ — $ 52 $ — Total return swap 8 — 8 — August 31, 2022 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 1,114 $ 1,114 $ — $ — Investments in debt securities 4 130 — 130 — Cross currency interest rate swaps 2 96 — 96 — Foreign currency forwards 3 69 — 69 — Investments in equity securities 5 1 1 — — Liabilities : Foreign currency forwards 3 $ 7 $ — $ 7 $ — Total return swaps 6 — 6 — 1 Money market funds are valued at the closing price reported by the fund sponsor and classified as marketable securities on the Consolidated Condensed Balance Sheets. 2 The fair value of cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 8. Financial instruments, for additional information. 3 The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 8. Financial instruments, for additional information. 4 Includes investments in Treasury debt securities. 5 Fair values of quoted investments are based on current bid prices. There were no transfers between Levels for the six months ended February 28, 2023. The carrying value of the Company's commercial paper and credit facilities approximated their respective fair values due to their short-term nature. The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the Consolidated Condensed Financial Statements. As of February 28, 2023 the carrying amounts and estimated fair values of long term notes outstanding including the current portion were $7.6 billion and $6.8 billion, respectively. The fair values of the notes outstanding are Level 1 fair value measures and determined based on quoted market price and translated at the February 28, 2023 rate, as applicable. The fair values and carrying values of these issuances do not include notes that have been redeemed or repaid as of February 28, 2023. See Note 7. Debt, for further information. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Feb. 28, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies The Company is involved in legal proceedings arising in the normal course of its business, including litigation, arbitration and other claims, and investigations, inspections, subpoenas, audits, claims, inquiries and similar actions by governmental authorities in pharmacy, healthcare, tax and other areas. Some of these proceedings may be class actions, and some involve claims for large or indeterminate amounts, including punitive or exemplary damages, and they may remain unresolved for several years. Legal proceedings in general, and securities, class action and multi-district litigation, in particular, can be expensive and disruptive. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The Company is subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which it operates. The Company’s business, compliance and reporting practices are subject to intensive scrutiny under applicable regulation, including review or audit by regulatory authorities. As a result, the Company regularly is the subject of government actions of the types described herein. The Company also may be named from time to time in qui tam actions initiated by private parties. In such an action, a private party purports to act on behalf of federal or state governments, alleges that false claims have been submitted for payment by the government and may receive an award if its claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on its own purporting to act on behalf of the government. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and suspension or exclusion from participation in government programs. We describe below certain proceedings against the Company in which the amount of loss could be material. We accrue for legal claims when, and to the extent that, the amount or range of probable loss can be reasonably estimated. We believe we have meritorious defenses in each of these proceedings, and we intend to defend each case vigorously, but there can be no assurance as to the ultimate outcome. With respect to litigation and other legal proceedings where the Company has determined a material loss is reasonably possible, except as otherwise disclosed, we are not able to make a reasonable estimate of the amount or range of loss that is reasonably possible above any accrued amounts in these proceedings, due to various reasons, including: we have factual and legal arguments that, if successful, will eliminate or sharply reduce the possibility of loss; we do not have sufficient information about the arguments and the evidence plaintiffs will advance with respect to their damages; some of the cases have been stayed; certain proceedings present novel and complex questions of public policy; legal and factual determinations and judicial and governmental procedure; the large number of parties involved; and the inherent uncertainties related to such litigations. Litigation Relating to 2016 Goals On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co. and Walgreen Co., as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. (Cutler v. Wasson et al., No. 1:14-cv-10408 (N.D. Ill.)) The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On May 18, 2015, the case was stayed in light of a securities class action that was filed on April 10, 2015 (Washtenaw County Employees’ Retirement System v. Walgreen Co. et al., No. 1:15-cv-3187 (N.D. Ill.). On November 3, 2016, the Court entered a stipulation and order extending the stay until the resolution of the securities class action. The securities class action was resolved and a final judgement order entered on October 13, 2022. On March 24, 2023, the plaintiff filed a motion for preliminary approval of a settlement resolving the litigation. On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. ( Washtenaw County Employees’ Retirement System v. Walgreen Co. et al. , No. 1:15-cv-3187 (N.D. Ill.)) The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The Company’s motion to dismiss the consolidated class action complaint filed on August 17, 2015 was granted in part and denied in part on September 30, 2016. The court granted plaintiff’s motion for class certification on March 29, 2018, and plaintiff filed a first amended complaint on December 19, 2018. A motion to dismiss the first amended complaint was granted in part and denied in part on September 23, 2019. Fact discovery and expert discovery have concluded. On November 2, 2021, the Court denied plaintiffs’ motion for summary judgment and granted in part and denied in part defendants’ cross motion. On March 2, 2022 the Court granted the Company’s motion to reconsider a portion of that ruling. On June 29, 2022 the Court granted preliminary approval of a settlement in the amount of $105 million, which was paid in fiscal 2022. The Court issued a final judgment order approving the settlement on October 13, 2022. Securities Claims Relating to Rite-Aid Merger On December 11, 2017, purported Rite Aid shareholders filed an amended complaint in a putative class action lawsuit in the U.S. District Court for the Middle District of Pennsylvania (the “M.D. Pa. class action”) arising out of transactions contemplated by the merger agreement between the Company and Rite Aid. The amended complaint alleges that the Company and certain of its officers made false or misleading statements regarding the transactions. The Court denied the Company’s motion to dismiss the amended complaint on April 15, 2019. The Company filed an answer and affirmative defenses, and the Court granted plaintiffs' motion for class certification. Fact and expert discovery have concluded and summary judgement briefing is complete. In October and December 2020, two separate purported Rite Aid Shareholders filed actions in the same court opting out of the class in the M.D. Pa. class action and making nearly identical allegations as those in the M.D. Pa. class action (the “Opt-out Actions”). The Opt-out Actions have been stayed until the earlier of (a) 30 days after the entry of an order resolving any pre-trial dispositive motions in the M.D. Pa. class action, or (b) 30 days after the entry of an order of final approval of any settlement of the M.D. Pa. class action. Claims Relating to Opioid Abuse The Company is among an array of defendants in multiple actions in federal courts alleging claims generally concerning the impacts of widespread opioid abuse, which have been commenced by various plaintiffs such as counties, cities, hospitals, Indian tribes, and others. In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated many of these cases in a consolidated multidistrict litigation, captioned In re National Prescription Opiate Litigation (MDL No. 2804, Case No. 17-md-2804), which is pending in the U.S. District Court for the Northern District of Ohio (“N.D. Ohio”). The Company is a defendant in the following multidistrict litigation (MDL) bellwether cases: • One case remanded to the U.S. District Court for the Northern District of California ( City and Cnty. of San Francisco, et al. v. Purdue Pharma L.P., et al. , Case No. 3:18-cv-07591-CRB). Following a bench trial, the court entered a liability finding against Walgreens in August 2022. The court scheduled a second trial regarding remedies for November 2022 to determine how much is to be paid, but that proceeding has been continued indefinitely. The Company has the right to appeal any judgment but is unable to predict the outcome relative to remedies or apportionment as well as the outcome of any appeal as the trial is ongoing. • Two cases in N.D. Ohio ( Cnty. of Lake, Ohio v. Purdue Pharma L.P., et al. , Case No. 18-op-45032; Cnty. of Trumbull, Ohio v. Purdue Pharma L.P., et al. , Case No. 18-op-45079). In November 2021, the jury in that case returned a verdict after trial in favor of the plaintiffs as to liability, and a second trial regarding remedies took place in May 2022. In August 2022, the court entered orders providing for injunctive relief and requiring the defendants to pay $650.6 million over a 15-year period to fund abatement programs. The court found that the damages are subject to joint and several liability and as such made no determination as to apportionment. These decisions are currently on appeal. • One case remanded to the U. S. District Court for the Eastern District of Oklahoma ( The Cherokee Nation v. McKesson Corp., et al. , Case No. 18-CV-00056-RAW-SPS), which was then remanded to the District Court of Sequoyah County, Oklahoma. The matter is stayed pursuant to a joint request from the parties. • Five additional bellwether cases designated in April 2021: (1) Cobb Cnty. v. Purdue Pharma L.P., et al. , Case No. 18-op-45817 (N.D. Georgia); (2) Durham Cnty. v. AmerisourceBergen Drug Corp., et al. , Case No. 19-op-45346 (M.D. North Carolina); (3) Montgomery Cnty. Bd. of Cnty. Commrs., et al. v. Cardinal Health, Inc., et al. , Case No. 18-op-46326 (S.D. Ohio); (4) Board of Cnty. Commrs. of the Cnty. of Santa Fe v. Purdue Pharma L.P., et al. , Case No. 18-op-45776 (D. New Mexico); and (5) Cnty. of Tarrant v. Purdue Pharma L.P., et al. , Case No. 18-op-45274 (N.D. Texas). • Two consolidated cases in N.D. Ohio ( Cnty. of Summit, Ohio, et al v. Purdue Pharma L.P., et al. , Case No. 18-op-45090; Cnty. of Cuyahoga, Ohio, et al. v. Purdue Pharma L.P. , Case No. 18-op-45004), previously scheduled for trial in November 2020 but postponed indefinitely. The Company also has been named as a defendant in numerous actions brought in state courts relating to opioid matters. Trial dates have been set in cases pending in state courts in the following states: • Nevada ( State of Nevada v. McKesson Corporation, et al. , Case No. A-19-796755-B, Eighth Judicial District Court, Clark County, Nevada - July 2023). • Missouri ( Jefferson County, Missouri v. Dannie E. Williams, M.D., et al. , Case No. 20JE-CC00029, Twenty-Third Judicial Circuit, Jefferson County, Missouri - July 2024). • Florida ( Florida Health Sciences Center, Inc., et al. v. Richard Sackler, et al. , Case No. CACE 19-018882, Seventeenth Judicial Circuit Court, Broward County, Florida - May 2025). The relief sought by various plaintiffs in these matters includes compensatory, abatement, restitution and punitive damages, as well as injunctive relief. Additionally, the Company has received from the U.S. Department of Justice (“DOJ”) and the Attorneys General of numerous states subpoenas, civil investigative demands, and other requests concerning opioid-related matters. The Company continues to communicate with the DOJ regarding purported violations of the federal Controlled Substances Act and the federal False Claims Act in dispensing prescriptions for opioids and other controlled substances at its pharmacies nationwide. On May 5, 2022, the Company announced that it had entered into a settlement agreement with the State of Florida to resolve all claims related to the distribution and dispensing of prescription opioid medications across the Company’s pharmacies in the State of Florida. This settlement agreement is not an admission of liability or wrong-doing and would resolve opioid lawsuits filed and future claims by the state and government subdivisions in the State of Florida. The estimated settlement amount of $683 million includes $620 million in remediation payments, which will be paid to the State of Florida in equal installments over 18 years, and will be applied as opioid remediation, as well as a one-time payment of $63 million for attorneys’ fees. In fiscal 2022, the Company recorded a $683 million liability associated with this settlement. On November 2, 2022, the Company announced that it had agreed to financial amounts and payment terms as part of settlement frameworks (the “Settlement Frameworks”) that have the potential to resolve a substantial majority of opioid-related lawsuits filed against the Company by the attorneys general of participating states and political subdivisions (the “Settling States”) and litigation brought by counsel for tribes. Under the Settlement Frameworks with the Settling States and counsel for tribes, the Company announced that it expected to settle all opioid claims against it by such Settling States, their participating political subdivisions, and participating tribes for up to approximately $4.8 billion and $155 million, respectively in remediation payments to be paid out over 15 years. The Settlement Frameworks provide for the payment of up to approximately $754 million in attorneys’ fees and costs over 6 years beginning in year two of the Settlement Frameworks. The Settlement Frameworks include no admission of wrongdoing or liability by the Company. As of November 30, 2022, the Company concluded that Settlement Framework discussions had advanced to a stage where a broad settlement of opioid claims by Settling States was probable, and for which the related loss was reasonably estimable. As a result of those conclusions and the Company’s ongoing assessment of other opioid-related claims, the Company recorded a $6.5 billion liability associated with the Settlement Frameworks and other opioid-related claims and litigation settlements during the three months ended November 30, 2022. The settlement accrual is reflected in the Consolidated Condensed Statement of Earnings within Selling, general and administrative expenses as part of the U.S. Retail Pharmacy segment. Loss contingencies are highly subjective, the Company cannot predict if any agreement will become effective, and unpredictable or unfavorable developments can occur. The amount of the actual loss may differ materially from the accrual estimate. On December 9, 2022, the Company committed the Settlement Frameworks to a proposed settlement agreement (the “Proposed Settlement Agreement”) that is contingent on (1) a sufficient number of Settling States, including those that have not sued, agreeing to the Proposed Settlement Agreement following a sign-on period, and (2) following a notice period, a sufficient number of political subdivisions within Settling States, including those that have not sued, agreeing to the Proposed Settlement Agreement (or otherwise having their claims foreclosed). Should some states or their political subdivisions decline to participate in the Proposed Settlement Agreement, but the Company nonetheless concludes that sufficient participation exists to warrant going forward with the settlement, during both of the two sign-on periods, there will be a corresponding reduction in the amount due from the Company to account for the entities that do not participate. Those non-participating Settling States or political subdivisions would be entitled to pursue their claims against the Company. The Company cannot predict if or when the Proposed Settlement Agreement will become effective. The Company will continue to vigorously defend against any litigation not covered by the Proposed Settlement Agreement, including private plaintiff litigation. The Company continues to believe it has strong legal defenses and appellate arguments in all of these cases. Usual and Customary Pricing Litigation

Income taxes

Income taxes	6 Months Ended
	Feb. 28, 2023
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The effective tax rate for the three months ended February 28, 2023 was 11.5%, compared to 18.2% for the three months ended February 28, 2022. The decrease in the effective tax rate was primarily due to the reduction in the valuation allowance and impact of the opioid-related claims and litigation settlements. The Company recognized a tax benefit due to the reduction of a valuation allowance previously recorded against deferred tax assets related to capital loss carryforwards. The reduction is primarily due to capital loss carryforwards utilized in the current period against capital gains recognized on the sale of shares in AmerisourceBergen. See Note 5. Equity method investments for further information. This benefit was partially offset by the impact of certain nondeductible opioid-related claims recorded in the three months ended February 28, 2023. The effective tax rate for the six months ended February 28, 2023 was a benefit of 29.5%, primarily due to a reduction in the valuation allowance and impact of the opioid-related claims and litigation settlements. The Company recognized a tax benefit due to the reduction of a valuation allowance previously recorded against deferred tax assets related to capital loss carryforwards. The reduction is primarily due to capital loss carryforwards utilized against capital gains recognized on the sale of shares in AmerisourceBergen and based on forecasted capital gains. This benefit was partially offset by the impact of certain nondeductible opioid-related claims recorded in the six months ended February 28, 2023. The effective tax rate for the six months ended February 28, 2022 was 9.4%, primarily due to lower tax expense on gains from consolidation of the Company’s investment in VillageMD and Shields, as a portion of these gains were not subject to tax. See Note 2. Acquisitions and other investments for further information. Income taxes paid for the six months ended February 28, 2023 and 2022 were $131 million and $201 million, respectively.

Retirement benefits

Retirement benefits	6 Months Ended
	Feb. 28, 2023
Retirement Benefits [Abstract]
Retirement benefits	Retirement benefits The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. Defined benefit pension plans (non-U.S. plans) The Company has various defined benefit pension plans outside the U.S. The principal defined benefit pension plan is the Boots Pension Plan (the “Boots Plan”), which covers certain employees in the UK. The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. Components of net periodic pension (income) costs for the defined benefit pension plans (in millions): Three months ended February 28, Six months ended February 28, Location in Consolidated Condensed Statements of Earnings 2023 2022 2023 2022 Service costs Selling, general and administrative expenses $ 1 $ 1 $ 2 $ 3 Interest costs Other income (expense), net 63 38 122 78 Expected returns on plan assets/other Other income (expense), net (80) (72) (156) (146) Total net periodic pension income $ (16) $ (33) $ (32) $ (65) The Company made cash contributions to its defined benefit pension plans of $11 million for the six months ended February 28, 2023, which primarily related to committed payments. The Company plans to contribute an additional $25 million to its defined benefit pension plans during the remainder of fiscal 2023. Defined contribution plans The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution is in the form of a guaranteed match which is made pursuant to the applicable plan document approved by the Walgreen Co. Board of Directors. Plan activity is reviewed periodically by certain Committees of the Walgreens Boots Alliance Board of Directors. The profit-sharing provision is an expense of $60 million and $125 million for the three and six months ended February 28, 2023, respectively, compared to an expense of $54 million and $123 million for the three and six months ended February 28, 2022, respectively. The Company also has certain contract based defined contribution arrangements. The principal one is UK based to which both the Company and participating employees contribute. The cost recognized in the Consolidated Condensed Statement of Earnings was $21 million and $41 million for the three and six months ended February 28, 2023, respectively, compared to an expense of $23 million and $48 million for the three and six months ended February 28, 2022, respectively.

Accumulated other comprehensive

Accumulated other comprehensive income (loss)	6 Months Ended
	Feb. 28, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated other comprehensive income (loss)	Accumulated other comprehensive income (loss) The following is a summary of net changes in accumulated other comprehensive income (loss) (“AOCI”) by component and net of tax for the three and six months ended February 28, 2023 and 2022 (in millions): Pension/ post- Unrealized loss on Net investment hedges Unrealized gain (loss) on available for sale securities Share of Cumulative translation adjustments Total Balance at November 30, 2022 $ (162) $ (5) $ 183 $ 1 $ (250) $ (2,583) $ (2,815) Other comprehensive (loss) income before reclassification adjustments — (1) (57) (1) 78 133 153 Amounts reclassified from AOCI (7) 1 — — 40 (11) 22 Tax benefit (provision) 2 — 14 — (30) — (15) Net change in other comprehensive (loss) income (5) — (43) (1) 88 122 161 Balance at February 28, 2023 $ (167) $ (5) $ 140 $ — $ (162) $ (2,461) $ (2,654) Pension/ post- Unrealized (loss) income on Net investment hedges Unrealized gain (loss) on available for sale securities Share of Cumulative translation adjustments Total Balance at August 31, 2022 $ (157) $ (3) $ 213 $ 1 $ (254) $ (2,605) $ (2,805) Other comprehensive (loss) income before reclassification adjustments — (3) (96) (1) (25) 158 33 Amounts reclassified from AOCI (13) — — — 150 (14) 123 Tax benefit (provision) 3 — 23 — (33) — (6) Net change in other comprehensive (loss) income (10) (2) (73) (1) 92 144 151 Balance at February 28, 2023 $ (167) $ (5) $ 140 $ — $ (162) $ (2,461) $ (2,654) Pension/ post- Unrealized (loss) income on Net investment hedges Share of Cumulative translation adjustments Total Balance at November 30, 2021 $ (364) $ (9) $ 9 $ (74) $ (1,863) $ (2,301) Other comprehensive income (loss) before reclassification adjustments 1 — (22) (105) 78 (48) Amounts reclassified from AOCI (5) 1 — — 3 (1) Other (6) — — — — (6) Tax benefit 2 — 2 26 — 29 Net change in other comprehensive (loss) income (8) — (20) (80) 81 (26) Balance at February 28, 2022 $ (372) $ (9) $ (11) $ (154) $ (1,782) $ (2,328) Pension/ post- Unrealized (loss) income on Net investment hedges Unrealized gain (loss) on available for sale securities Share of Cumulative translation adjustments Total Balance at August 31, 2021 $ (359) $ (10) $ (35) $ 96 $ (29) $ (1,772) $ (2,109) Other comprehensive income (loss) before reclassification adjustments — — 31 450 (165) (9) 307 Amounts reclassified from AOCI (11) 1 — (577) — (1) (587) Other (6) — — — — — (6) Tax benefit (provision) 3 (1) (8) 31 40 — 66 Net change in other comprehensive (loss) income (13) 1 24 (96) (125) (10) (220) Balance at February 28, 2022 $ (372) $ (9) $ (11) $ — $ (154) $ (1,782) $ (2,328)

Segment reporting

Segment reporting	6 Months Ended
	Feb. 28, 2023
Segment Reporting [Abstract]
Segment reporting	Segment reporting The Company is aligned into three reportable segments: U.S. Retail Pharmacy, International and U.S. Healthcare. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included. U.S. Retail Pharmacy The Company's U.S. Retail Pharmacy segment includes the Walgreens business which is comprised of the operations of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and its equity method investment in AmerisourceBergen. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise. International The Company's International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and a pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, the Benavides brand in Mexico and the Ahumada brand in Chile. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products. U.S. Healthcare The Company’s U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omni-channel experience across the care journey. The U.S. Healthcare segment delivers improved health outcomes and lower costs for payors and providers by delivering care through owned and partnered assets. The U.S. Healthcare segment currently consists of a majority position in VillageMD, a leading national provider of value-based primary, urgent and multi-specialty care services; Shields, a specialty pharmacy integrator and accelerator for hospitals; a majority position in CareCentrix, a leading player in the post-acute and home care management sectors, and the Walgreens Health organic business that contracts with payors and providers to deliver clinical healthcare services to their members and members’ caregivers through both digital and physical channels. The results of operations for reportable segments include procurement benefits. Corporate-related overhead costs are not allocated to reportable segments and are reported in “Corporate and Other”. The following table reflects results of operations of the Company’s reportable segments (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Sales: U.S. Retail Pharmacy $ 27,577 $ 27,667 $ 54,781 $ 55,699 International 5,651 5,563 10,840 11,381 U.S. Healthcare 1,634 527 2,622 577 Corporate and Other — (1) — (1) Walgreens Boots Alliance, Inc. $ 34,862 $ 33,756 $ 68,244 $ 67,656 Adjusted operating income (Non-GAAP measure): U.S. Retail Pharmacy $ 1,067 $ 1,588 $ 2,172 $ 3,277 International 352 226 468 389 U.S. Healthcare (159) (77) (311) (90) Corporate and Other (44) (79) (100) (143) Walgreens Boots Alliance, Inc. $ 1,215 $ 1,657 $ 2,229 $ 3,434 The following table reconciles adjusted operating income to operating income (loss) (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Adjusted operating income (Non-GAAP measure) $ 1,215 $ 1,657 $ 2,229 $ 3,434 Certain legal and regulatory accruals and settlements (427) — (6,981) — Acquisition-related amortization (247) (250) (577) (415) Acquisition-related costs (148) (44) (187) (115) Transformational cost management (145) (70) (283) (273) Adjustments to equity earnings in AmerisourceBergen (31) (51) (117) (94) LIFO provision (20) 5 (38) (9) Operating income (loss) (GAAP measure) $ 197 $ 1,246 $ (5,954) $ 2,529

Sales

Sales	6 Months Ended
	Feb. 28, 2023
Revenue from Contract with Customer [Abstract]
Sales	Sales The following table summarizes the Company’s sales by segment and by major source (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 U.S. Retail Pharmacy Pharmacy $ 19,874 $ 19,820 $ 40,092 $ 40,925 Retail 7,703 7,847 14,689 14,774 Total 27,577 27,667 54,781 55,699 International Pharmacy 898 958 1,766 1,975 Retail 1,994 1,880 3,643 3,676 Wholesale 2,759 2,725 5,431 5,730 Total 5,651 5,563 10,840 11,381 U.S. Healthcare 1,634 527 2,622 577 Corporate and Other 1 — (1) — (1) Walgreens Boots Alliance, Inc. $ 34,862 $ 33,756 $ 68,244 $ 67,656 1. Includes certain eliminations. See Note 18. Supplemental information for further information on receivables from contracts with customers.

Related parties

Related parties	6 Months Ended
	Feb. 28, 2023
Related Party Transactions [Abstract]
Related parties	Related parties The Company has a long-term pharmaceutical distribution agreement with AmerisourceBergen pursuant to which the Company sources branded and generic pharmaceutical products from AmerisourceBergen. Additionally, AmerisourceBergen receives sourcing services for generic pharmaceutical products. Related party transactions with AmerisourceBergen (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Purchases, net $ 15,759 $ 15,063 $ 31,199 $ 30,854 February 28, 2023 August 31, 2022 Trade accounts payable, net of Trade accounts receivable $ 7,839 $ 6,915

New accounting pronouncements

New accounting pronouncements	6 Months Ended
	Feb. 28, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
New accounting pronouncements	Accounting policies Basis of presentation The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest and certain variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated. The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2022, as amended by Form 10-K/A for the fiscal year ended August 31, 2022 filed on November 23, 2022. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of opioid-related claims and litigation settlements, COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payor and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years. Certain amounts in the Consolidated Condensed Financial Statements and associated notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented. Adoption of new accounting pronouncements Disclosures by business entities about government assistance In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The Company adopted the new standard effective September 1, 2022, and the adoption did not impact the Company's disclosures within these consolidated condensed financial statements. New accounting pronouncements not yet adopted Acquired contract assets and contract liabilities in a business combination In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance. Liabilities—Supplier Finance Programs In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Topic 405-50) - Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. This ASU is expected to improve financial reporting by requiring new disclosures about the programs, thereby allowing financial statement users to better consider the effect of the programs on an entity’s working capital, liquidity, and cash flows. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024), except for the amendment on roll forward information which is effective for fiscal years beginning after December 15, 2023 (fiscal 2025). The Company is evaluating the effect of adopting this new accounting guidance.

Supplemental information

Supplemental information	6 Months Ended
	Feb. 28, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental information	Supplemental information Accounts receivable Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, including amounts due from third party payors (e.g., pharmacy benefit managers, insurance companies and governmental agencies). Trade receivables were $4.3 billion and $4.0 billion at February 28, 2023 and August 31, 2022, respectively. Other accounts receivable balances, which consist primarily of receivables from vendors and manufacturers, including receivables from AmerisourceBergen, were $1.4 billion and $1.1 billion at February 28, 2023 and August 31, 2022, respectively. See Note 16. Related parties for further information. Depreciation and amortization The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Depreciation expense $ 361 $ 348 $ 697 $ 683 Intangible assets amortization 199 175 357 340 Total depreciation and amortization expense $ 559 $ 524 $ 1,055 $ 1,024 Accumulated depreciation and amortization on property, plant and equipment was $12.8 billion at February 28, 2023 and $12.8 billion at August 31, 2022. Restricted cash The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. The following represents a reconciliation of Cash and cash equivalents in the Consolidated Condensed Balance Sheets to total Cash, cash equivalents, marketable securities and restricted cash in the Consolidated Condensed Statements of Cash Flows as of February 28, 2023 and August 31, 2022, respectively (in millions): February 28, 2023 August 31, 2022 Cash and cash equivalents $ 1,088 $ 1,358 Marketable securities 752 1,114 Restricted cash (included in other current and non-current assets) 153 86 Cash, cash equivalents, marketable securities and restricted cash $ 1,993 $ 2,558 Redeemable non-controlling interest The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Opening balance $ 157 $ 2,787 $ 1,042 $ 319 Recognition upon acquisition of subsidiary 1 — — — 2,489 Acquisition of non-controlling interests 2 — (2,047) — (2,047) Net loss attributable to Redeemable non-controlling interests (1) (12) (24) (33) Redemption price adjustments 3 — 83 440 90 Reclassifications to Accrued expenses and other liabilities 4 — — (1,314) — Other 3 2 14 (6) Ending balance $ 158 $ 812 $ 158 $ 812 1. The six months ended February 28, 2022, includes $1.9 billion of redeemable non-controlling interest, representing the maximum purchase price to redeem non-controlling units in VillageMD for cash, and redeemable non-controlling interest in Shields. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement. 2. The three and six months ended February 28, 2022 includes, $1.9 billion paid to existing shareholders of VillageMD as part of the fully subscribed tender offer and the acquisition of the remaining 30% non-controlling equity interests in the pharmaceutical wholesale business in Germany. 3. Remeasurement of non-controlling interests, probable of redemption but not currently redeemable, to their redemption value, is recorded to Paid in capital in the Consolidated Condensed Balance Sheets. During the three months ended November 30, 2022, the Company announced the acceleration of its plans for full ownership of Shields and CareCentrix. The Shields and CareCentrix redeemable non-controlling interests were recorded to redemption value. 4. Represents the reclassification of the Shields and CareCentrix redeemable non-controlling interests to Accrued expenses and other liabilities, resulting from acceleration of the Company's plans for full ownership of Shields and CareCentrix. See Note 2. Acquisitions and other investments for further information. Earnings per share The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 16.0 million and 16.8 million weighted outstanding options to purchase common shares that were anti-dilutive and excluded from the earnings per share calculation for the three and six months ended February 28, 2023, compared to 17.9 million and 16.9 million for the three and six months ended February 28, 2022, respectively. Due to the anti-dilutive effect resulting from the reported net loss, an incremental 4.8 million of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding for the six months ended February 28, 2023. Cash dividends declared per common share Cash dividends per common share declared were as follows: Quarter ended 2023 2022 November $ 0.4800 $ 0.4775 February $ 0.4800 $ 0.4775 Total $ 0.9600 $ 0.9550

Subsequent events

Subsequent events	6 Months Ended
	Feb. 28, 2023
Subsequent Events [Abstract]
Subsequent events	Subsequent events 2023 Revolving Credit Agreement On March 2, 2023, the Company entered into a $900 million unsecured 364-day revolving credit facility (the “2023 Revolving Credit Agreement”) with a termination date of February 29, 2024, or earlier, subject to the Company's discretion. Borrowings under the 2023 Revolving Credit Agreement bear interest at fluctuating rate per annum equal to, at the Company’s option, the alternate base rate, the term SOFR or the daily SOFR, in each case, plus an applicable margin. The applicable margin is in each case based on the rating of the Company’s corporate debt obligations as determined by Moody’s or S&P.

Accounting policies (Policies)

Accounting policies (Policies)	6 Months Ended
	Feb. 28, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest and certain variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated. The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2022, as amended by Form 10-K/A for the fiscal year ended August 31, 2022 filed on November 23, 2022. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. The impact of opioid-related claims and litigation settlements, COVID-19, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payor and customer relationships and terms, strategic transactions including acquisitions, dispositions, changes in laws and general economic conditions in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years.
Adoption of new accounting pronouncements; New accounting pronouncements not yet adopted	Adoption of new accounting pronouncements Disclosures by business entities about government assistance In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832) – Disclosures by Business Entities about Government Assistance. This ASU requires disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the types of transactions, (2) the accounting for those transactions, and (3) the effect of those transactions on an entity’s financial statements. The Company adopted the new standard effective September 1, 2022, and the adoption did not impact the Company's disclosures within these consolidated condensed financial statements. New accounting pronouncements not yet adopted Acquired contract assets and contract liabilities in a business combination In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024). The Company is evaluating the effect of adopting this new accounting guidance. Liabilities—Supplier Finance Programs In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Topic 405-50) - Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. This ASU is expected to improve financial reporting by requiring new disclosures about the programs, thereby allowing financial statement users to better consider the effect of the programs on an entity’s working capital, liquidity, and cash flows. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024), except for the amendment on roll forward information which is effective for fiscal years beginning after December 15, 2023 (fiscal 2025). The Company is evaluating the effect of adopting this new accounting guidance.

Acquisitions and other invest_2

Acquisitions and other investments (Tables)	6 Months Ended
	Feb. 28, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Identifiable Assets Acquired and Liabilities Assumed	The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Cash consideration 1 $ 4,790 Deferred consideration 100 Summit debt paid at closing 1,963 Fair value of equity consideration 1,980 Total $ 8,833 Identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 75 Accounts receivable, net 361 Property, plant and equipment 593 Intangible assets 2 3,359 Operating lease right-of-use assets 757 Other assets 192 Operating lease obligations (773) Deferred tax liability (918) Other liabilities (507) Total identifiable net assets $ 3,139 Goodwill $ 5,693 1. Cash considerations excludes $86 million of cash paid to fund acquisition-related bonuses to Summit employees which is recognized as compensation expense of the Company. 2. Intangibles acquired include provider networks and trade names with fair values of $1.9 billion and $1.5 billion, respectively. Estimated useful lives are 16 years and 11 to 15 years, respectively. The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Total purchase price $ 5,200 Less: purchase price for issuance of new preferred units at fair value 1 (2,300) Net consideration 2,900 Fair value of share-based compensation awards attributable to pre-combination services 2 683 Fair value of previously held equity and debt 3,211 Fair value of non-controlling interests 3,257 Total $ 10,051 Identifiable assets acquired and liabilities assumed: Tangible assets 1 $ 634 Intangible assets 3 1,621 Liabilities (370) Total identifiable net assets $ 1,885 Goodwill $ 8,166 1. Comprised of cash consideration of $1.1 billion and a promissory note of $1.2 billion. This consideration was provided in exchange for the issuance of new preferred units by VillageMD. VillageMD’s tangible assets acquired exclude this $1.1 billion of cash and $1.2 billion promissory note receivable. 2. Primarily related to vested share-based compensation awards. 3. Intangibles acquired include primary care provider network, trade names and developed technology, with a fair value of $1.2 billion, $295 million and $76 million, respectively. Estimated useful lives are 15, 13 and 5 years, respectively. The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Cash consideration $ 969 Fair value of share-based compensation awards attributable to pre-combination services 13 Fair value of previously held equity interests 502 Fair value of non-controlling interests 589 Total $ 2,074 Identifiable assets acquired and liabilities assumed: Tangible assets $ 84 Intangible assets 1 1,060 Liabilities (600) Total identifiable net assets $ 544 Goodwill $ 1,529 1. Intangibles acquired include customer relationships, trade names and developed technology, with a fair value of $896 million, $47 million and $117 million, respectively. Estimated useful lives are 13, 13 and 5 years, respectively. The following table summarizes the consideration for the acquisition and the preliminary amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation: Cash consideration 1 $ 327 Contingent consideration 4 Fair value of share-based compensation awards attributable to pre-combination services 66 Fair value of non-controlling interests 217 Total $ 614 Identifiable assets acquired and liabilities assumed: Tangible assets $ 358 Intangible assets 2 426 Liabilities (680) Total identifiable net assets $ 104 Goodwill $ 509 1. Excludes $12 million of cash paid to employees, which was recognized as compensation expense by the Company. 2. Intangibles acquired include customer relationships, trade names and developed technology, with a fair value of $247 million, $93 million and $86 million, respectively. Estimated useful lives are 13, 13 and 5 years, respectively.
Schedule of Pro Forma Information	Three months ended February 28, Six months ended February 28, (Unaudited, in millions) 2023 2022 2023 2022 Sales $ 35,119 $ 34,402 $ 69,216 $ 68,924 Actual sales of Summit, from the acquisition date, for the three and six months ended February 28, 2023, included in the Consolidated Condensed Statements of Earnings are as follows: Three and six months ended February 28, (in millions) 2023 Sales $ 463 Three months ended February 28, Six months ended February 28, (Unaudited, in millions) 2022 2022 Sales $ 34,063 $ 68,627 Actual sales of the acquired companies for the three and six months ended February 28, 2022, included in the Consolidated Condensed Statements of Earnings are as follows: Three months ended February 28, Six months ended February 28, (in millions) 2022 2022 Sales $ 527 $ 577

Exit and disposal activities (T

Exit and disposal activities (Tables)	6 Months Ended
	Feb. 28, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Costs related to exit and disposal activities under the Transformational Cost Management Program for the three and six months ended February 28, 2023 and 2022, respectively, were as follows (in millions): Three months ended February 28, 2023 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 20 $ — $ — $ 20 Asset impairments 96 (1) — 95 Employee severance and business transition costs 11 1 3 15 Information technology transformation and other exit costs 4 5 (1) 9 Total exit and disposal charges $ 131 $ 4 $ 2 $ 138 Six months ended February 28, 2023 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 98 $ — $ — $ 98 Asset impairments 115 (1) — 113 Employee severance and business transition costs 22 2 7 31 Information technology transformation and other exit costs 16 10 (1) 25 Total exit and disposal charges $ 250 $ 10 $ 6 $ 267 Three months ended February 28, 2022 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 5 $ 1 $ — $ 5 Asset impairments 1 3 — 4 Employee severance and business transition costs 36 — 5 41 Information technology transformation and other exit costs 1 4 — 5 Total exit and disposal charges $ 43 $ 8 $ 5 $ 56 Six months ended February 28, 2022 U.S. Retail Pharmacy International Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 91 $ 3 $ — $ 95 Asset impairments 16 28 — 44 Employee severance and business transition costs 56 9 14 79 Information technology transformation and other exit costs 2 11 — 13 Total exit and disposal charges $ 166 $ 51 $ 14 $ 231
Change in Restructuring Liabilities	The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions): Lease obligations and other real estate costs Asset Impairments Employee severance and business transition costs Information technology transformation and other exit costs Total Balance at August 31, 2022 $ 10 $ — $ 76 $ 27 $ 113 Costs 98 113 31 25 267 Payments (51) — (72) (17) (139) Other (57) (113) 1 — (170) Balance at February 28, 2023 $ — $ — $ 36 $ 36 $ 72

Leases (Tables)

Leases (Tables)	6 Months Ended
	Feb. 28, 2023
Leases [Abstract]
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases were as follows (in millions): Balance Sheet supplemental information: February 28, 2023 August 31, 2022 Operating leases: Operating lease right-of-use assets $ 22,024 $ 21,259 Operating lease obligations - current 2,340 2,286 Operating lease obligations - non-current 22,195 21,517 Total operating lease obligations $ 24,534 $ 23,803 Finance leases: Right-of-use assets included in: Property, plant and equipment, net $ 694 $ 645 Lease obligations included in: Accrued expenses and other liabilities 53 37 Other non-current liabilities 931 899 Total finance lease obligations $ 984 $ 936
Schedule of Supplemental Income Statement and Other Information	Supplemental income statement information related to leases were as follows (in millions): Three months ended February 28, Six months ended February 28, Statement of Earnings supplemental information: 2023 2022 2023 2022 Operating lease cost Fixed $ 853 $ 815 $ 1,667 $ 1,619 Variable 1 203 197 395 402 Finance lease cost Amortization $ 11 $ 11 $ 21 $ 22 Interest 12 13 24 26 Sublease income $ 28 $ 26 $ 57 $ 51 Impairment of right-of-use assets 4 3 71 71 Gain on sale and leaseback 2 U.S. Retail Pharmacy $ 211 $ 148 $ 384 $ 235 International 3 132 — 148 — Total gain on sale and leaseback 2 $ 343 $ 148 $ 532 $ 235 1 Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume. 2 Recorded within Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. 3 Includes gain on sale and leaseback related to Germany wholesale business of $132 million and $148 million for the three and six months ended February 2023, respectively, of which $24 million and $41 million related to the optimization of warehouse locations as part of acquisition integration activities. Six months ended February 28, Other supplemental information: 2023 2022 Cash paid for amounts included in the measurement of lease obligations Operating cash flows from operating leases $ 1,720 $ 1,666 Operating cash flows from finance leases 22 23 Financing cash flows from finance leases 21 21 Total $ 1,763 $ 1,710 Right-of-use assets obtained in exchange for new lease obligations Operating leases $ 1,135 $ 1,005 Finance leases 18 11 Total $ 1,154 $ 1,016 Weighted average lease term and discount rate for real estate leases were as follows: Weighted average lease terms and discount rates: February 28, 2023 August 31, 2022 Weighted average remaining lease term in years Operating leases 9.8 10.0 Finance leases 17.7 19.0 Weighted average discount rate Operating leases 5.26 % 4.83 % Finance leases 5.26 % 5.19 %
Schedule of Aggregate Future Lease Payments Under Operating Leases	The aggregate future lease payments for operating and finance leases as of February 28, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2023 (Remaining period) $ 53 $ 1,805 2024 105 3,555 2025 101 3,450 2026 98 3,361 2027 97 3,266 2028 88 3,108 Later 958 12,980 Total undiscounted minimum lease payments $ 1,501 $ 31,524 Less: Present value discount 516 6,990 Lease liability $ 984 $ 24,534
Schedule of Aggregate Future Lease Payments Under Finance Leases	The aggregate future lease payments for operating and finance leases as of February 28, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2023 (Remaining period) $ 53 $ 1,805 2024 105 3,555 2025 101 3,450 2026 98 3,361 2027 97 3,266 2028 88 3,108 Later 958 12,980 Total undiscounted minimum lease payments $ 1,501 $ 31,524 Less: Present value discount 516 6,990 Lease liability $ 984 $ 24,534

Equity method investments (Tabl

Equity method investments (Tables)	6 Months Ended
	Feb. 28, 2023
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Equity Method Investments	Equity method investments were as follows (in millions, except percentages): February 28, 2023 August 31, 2022 Carrying value Ownership percentage Carrying value Ownership percentage AmerisourceBergen $ 2,563 17% $ 3,916 25% Others 1,506 4% - 50% 1,579 8% - 50% Total $ 4,069 $ 5,495

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	6 Months Ended
	Feb. 28, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill by reportable segment consist of the following (in millions): Goodwill roll forward: U.S. Retail Pharmacy International U.S. Healthcare Walgreens Boots Alliance, Inc. August 31, 2022 $ 10,947 $ 1,293 $ 10,040 $ 22,280 Acquisitions — — 5,735 5,735 Adjustments 1 — — 252 252 Currency translation adjustments — 76 — 76 February 28, 2023 $ 10,947 $ 1,369 $ 16,027 $ 28,343 1 Includes measurement period adjustments related to acquisition of VillageMD, Shields and CareCentrix. See Note 2. Acquisitions and other investments for further information.
Schedule of Finite-Lived Intangible Assets by Major Class	The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): Intangible assets: February 28, 2023 August 31, 2022 Gross amortizable intangible assets Customer relationships and loyalty card holders 1 $ 4,466 $ 4,619 Provider networks 3,099 1,247 Trade names and trademarks 2,271 760 Developed technology 442 436 Others 95 93 Total gross amortizable intangible assets $ 10,373 $ 7,155 Accumulated amortization Customer relationships and loyalty card holders 1 $ 1,574 $ 1,548 Provider networks 126 64 Trade names and trademarks 301 246 Developed technology 92 56 Others 43 39 Total accumulated amortization 2,136 1,953 Total amortizable intangible assets, net $ 8,237 $ 5,202 Indefinite-lived intangible assets Trade names and trademarks $ 4,397 $ 4,319 Pharmacy licenses 1,231 1,209 Total indefinite-lived intangible assets $ 5,628 $ 5,528 Total intangible assets, net $ 13,864 $ 10,730 1 Includes purchased prescription files.
Schedule of Future Amortization Expense	Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at February 28, 2023 is as follows (in millions): 2023 (Remaining period) 2024 2025 2026 2027 2028 Estimated annual amortization expense $ 431 $ 846 $ 814 $ 796 $ 733 $ 674

Debt (Tables)

Debt (Tables)	6 Months Ended
	Feb. 28, 2023
Debt Disclosure [Abstract]
Short-Term Borrowings	Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): February 28, 2023 August 31, 2022 Short-term debt Commercial paper 1 $ 1,296 $ — Credit facilities 1 Unsecured 364-day credit facility due 2023 — 1,000 Unsecured two 1,999 — $850 million note issuance 1 0.9500% unsecured notes due 2023 849 — Other 2 79 59 Total short-term debt $ 4,222 $ 1,059 Long-term debt Credit facilities 1 Unsecured two $ — $ 1,998 Unsecured three 999 999 Unsecured three 999 — $850 million note issuance 1 0.9500% unsecured notes due 2023 — 848 $1.5 billion note issuance 1 3.200% unsecured notes due 2030 498 498 4.100% unsecured notes due 2050 792 792 $6 billion note issuance 1 3.450% unsecured notes due 2026 1,443 1,443 4.650% unsecured notes due 2046 318 318 $8 billion note issuance 1 3.800% unsecured notes due 2024 1,155 1,155 4.500% unsecured notes due 2034 301 301 4.800% unsecured notes due 2044 869 869 £700 million note issuance 1 3.600% unsecured pound sterling notes due 2025 361 354 €750 million note issuance 1 2.125% unsecured euro notes due 2026 799 752 $4 billion note issuance 3 4.400% unsecured notes due 2042 263 263 Other 2 23 26 Total long-term debt, less current portion $ 8,820 $ 10,615 1 Notes, borrowings under credit facilities and commercial paper are unsecured and unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding. 2 Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. 3 Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.
Long-Term Debt	Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): February 28, 2023 August 31, 2022 Short-term debt Commercial paper 1 $ 1,296 $ — Credit facilities 1 Unsecured 364-day credit facility due 2023 — 1,000 Unsecured two 1,999 — $850 million note issuance 1 0.9500% unsecured notes due 2023 849 — Other 2 79 59 Total short-term debt $ 4,222 $ 1,059 Long-term debt Credit facilities 1 Unsecured two $ — $ 1,998 Unsecured three 999 999 Unsecured three 999 — $850 million note issuance 1 0.9500% unsecured notes due 2023 — 848 $1.5 billion note issuance 1 3.200% unsecured notes due 2030 498 498 4.100% unsecured notes due 2050 792 792 $6 billion note issuance 1 3.450% unsecured notes due 2026 1,443 1,443 4.650% unsecured notes due 2046 318 318 $8 billion note issuance 1 3.800% unsecured notes due 2024 1,155 1,155 4.500% unsecured notes due 2034 301 301 4.800% unsecured notes due 2044 869 869 £700 million note issuance 1 3.600% unsecured pound sterling notes due 2025 361 354 €750 million note issuance 1 2.125% unsecured euro notes due 2026 799 752 $4 billion note issuance 3 4.400% unsecured notes due 2042 263 263 Other 2 23 26 Total long-term debt, less current portion $ 8,820 $ 10,615 1 Notes, borrowings under credit facilities and commercial paper are unsecured and unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding. 2 Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. 3 Notes are senior debt obligations of Walgreen Co. and rank equally with all other unsecured and unsubordinated indebtedness of Walgreen Co. On December 31, 2014, the Company fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of the Company and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company.

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
	Feb. 28, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Notional Amounts, Fair Value and Balance Sheet Presentation of Derivative Instruments Outstanding	The notional amounts and fair value of derivative instruments outstanding were as follows (in millions): February 28, 2023 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 319 $ 6 Other current assets Cross currency interest rate swaps 100 3 Other current assets Cross currency interest rate swaps 650 55 Other non-current assets Foreign currency forwards 8 — Other non-current assets Foreign currency forwards 470 4 Other current liabilities Foreign currency forwards 4 — Other non-current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 1,831 $ 20 Other current assets Foreign currency forwards 2,065 48 Other current liabilities Total return swap 217 8 Other current liabilities August 31, 2022 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 448 $ 19 Other current assets Cross currency interest rate swaps 150 12 Other current assets Cross currency interest rate swaps 750 83 Other non-current assets Foreign currency forwards 3 — Other non-current assets Foreign currency forwards 221 1 Other current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 2,874 $ 49 Other current assets Foreign currency forwards 1,098 6 Other current liabilities Total return swap 183 6 Other current liabilities
Gains and (Losses) due to Changes in Fair Value Recognized in Earnings	The income (expenses) due to changes in fair value of the derivative instruments were recognized in Consolidated Condensed Statements of Earnings as follows (in millions): Three months ended February 28, Six months ended February 28, Location in Consolidated Condensed Statements of Earnings 2023 2022 2023 2022 Foreign currency forwards Selling, general and administrative expenses 1 $ — $ (51) $ — $ 4 Total return swap Selling, general and administrative expenses (3) (8) — (10) Foreign currency forwards Other income (expense), net 1,2 (73) — (92) (1) 1. In fiscal 2023, certain expenses related to derivative instruments used as economic hedges, were presented as Other income (expense), net within the Consolidated Condensed Statements of Earnings, whereas these expenses were recorded within Selling, general, and administrative expenses within the Consolidated Condensed Statements of Earnings in prior periods. 2. Excludes remeasurement gains and losses on economically hedged assets and liabilities.

Fair value measurements (Tables

Fair value measurements (Tables)	6 Months Ended
	Feb. 28, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows (in millions): February 28, 2023 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 752 $ 752 $ — $ — Cross currency interest rate swaps 2 58 — 58 — Foreign currency forwards 3 27 — 27 — Liabilities : Foreign currency forwards 3 $ 52 $ — $ 52 $ — Total return swap 8 — 8 — August 31, 2022 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 1,114 $ 1,114 $ — $ — Investments in debt securities 4 130 — 130 — Cross currency interest rate swaps 2 96 — 96 — Foreign currency forwards 3 69 — 69 — Investments in equity securities 5 1 1 — — Liabilities : Foreign currency forwards 3 $ 7 $ — $ 7 $ — Total return swaps 6 — 6 — 1 Money market funds are valued at the closing price reported by the fund sponsor and classified as marketable securities on the Consolidated Condensed Balance Sheets. 2 The fair value of cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 8. Financial instruments, for additional information. 3 The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 8. Financial instruments, for additional information. 4 Includes investments in Treasury debt securities. 5 Fair values of quoted investments are based on current bid prices.

Retirement benefits (Tables)

Retirement benefits (Tables)	6 Months Ended
	Feb. 28, 2023
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Costs (Income)	Components of net periodic pension (income) costs for the defined benefit pension plans (in millions): Three months ended February 28, Six months ended February 28, Location in Consolidated Condensed Statements of Earnings 2023 2022 2023 2022 Service costs Selling, general and administrative expenses $ 1 $ 1 $ 2 $ 3 Interest costs Other income (expense), net 63 38 122 78 Expected returns on plan assets/other Other income (expense), net (80) (72) (156) (146) Total net periodic pension income $ (16) $ (33) $ (32) $ (65)

Accumulated other comprehensi_2

Accumulated other comprehensive income (loss) (Tables)	6 Months Ended
	Feb. 28, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Components of Accumulated Other Comprehensive Income (Loss)	The following is a summary of net changes in accumulated other comprehensive income (loss) (“AOCI”) by component and net of tax for the three and six months ended February 28, 2023 and 2022 (in millions): Pension/ post- Unrealized loss on Net investment hedges Unrealized gain (loss) on available for sale securities Share of Cumulative translation adjustments Total Balance at November 30, 2022 $ (162) $ (5) $ 183 $ 1 $ (250) $ (2,583) $ (2,815) Other comprehensive (loss) income before reclassification adjustments — (1) (57) (1) 78 133 153 Amounts reclassified from AOCI (7) 1 — — 40 (11) 22 Tax benefit (provision) 2 — 14 — (30) — (15) Net change in other comprehensive (loss) income (5) — (43) (1) 88 122 161 Balance at February 28, 2023 $ (167) $ (5) $ 140 $ — $ (162) $ (2,461) $ (2,654) Pension/ post- Unrealized (loss) income on Net investment hedges Unrealized gain (loss) on available for sale securities Share of Cumulative translation adjustments Total Balance at August 31, 2022 $ (157) $ (3) $ 213 $ 1 $ (254) $ (2,605) $ (2,805) Other comprehensive (loss) income before reclassification adjustments — (3) (96) (1) (25) 158 33 Amounts reclassified from AOCI (13) — — — 150 (14) 123 Tax benefit (provision) 3 — 23 — (33) — (6) Net change in other comprehensive (loss) income (10) (2) (73) (1) 92 144 151 Balance at February 28, 2023 $ (167) $ (5) $ 140 $ — $ (162) $ (2,461) $ (2,654) Pension/ post- Unrealized (loss) income on Net investment hedges Share of Cumulative translation adjustments Total Balance at November 30, 2021 $ (364) $ (9) $ 9 $ (74) $ (1,863) $ (2,301) Other comprehensive income (loss) before reclassification adjustments 1 — (22) (105) 78 (48) Amounts reclassified from AOCI (5) 1 — — 3 (1) Other (6) — — — — (6) Tax benefit 2 — 2 26 — 29 Net change in other comprehensive (loss) income (8) — (20) (80) 81 (26) Balance at February 28, 2022 $ (372) $ (9) $ (11) $ (154) $ (1,782) $ (2,328) Pension/ post- Unrealized (loss) income on Net investment hedges Unrealized gain (loss) on available for sale securities Share of Cumulative translation adjustments Total Balance at August 31, 2021 $ (359) $ (10) $ (35) $ 96 $ (29) $ (1,772) $ (2,109) Other comprehensive income (loss) before reclassification adjustments — — 31 450 (165) (9) 307 Amounts reclassified from AOCI (11) 1 — (577) — (1) (587) Other (6) — — — — — (6) Tax benefit (provision) 3 (1) (8) 31 40 — 66 Net change in other comprehensive (loss) income (13) 1 24 (96) (125) (10) (220) Balance at February 28, 2022 $ (372) $ (9) $ (11) $ — $ (154) $ (1,782) $ (2,328)

Segment reporting (Tables)

Segment reporting (Tables)	6 Months Ended
	Feb. 28, 2023
Segment Reporting [Abstract]
Reconciliation of Operating Income (Loss) from Segments to Consolidated	The following table reflects results of operations of the Company’s reportable segments (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Sales: U.S. Retail Pharmacy $ 27,577 $ 27,667 $ 54,781 $ 55,699 International 5,651 5,563 10,840 11,381 U.S. Healthcare 1,634 527 2,622 577 Corporate and Other — (1) — (1) Walgreens Boots Alliance, Inc. $ 34,862 $ 33,756 $ 68,244 $ 67,656 Adjusted operating income (Non-GAAP measure): U.S. Retail Pharmacy $ 1,067 $ 1,588 $ 2,172 $ 3,277 International 352 226 468 389 U.S. Healthcare (159) (77) (311) (90) Corporate and Other (44) (79) (100) (143) Walgreens Boots Alliance, Inc. $ 1,215 $ 1,657 $ 2,229 $ 3,434 The following table reconciles adjusted operating income to operating income (loss) (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Adjusted operating income (Non-GAAP measure) $ 1,215 $ 1,657 $ 2,229 $ 3,434 Certain legal and regulatory accruals and settlements (427) — (6,981) — Acquisition-related amortization (247) (250) (577) (415) Acquisition-related costs (148) (44) (187) (115) Transformational cost management (145) (70) (283) (273) Adjustments to equity earnings in AmerisourceBergen (31) (51) (117) (94) LIFO provision (20) 5 (38) (9) Operating income (loss) (GAAP measure) $ 197 $ 1,246 $ (5,954) $ 2,529

Sales (Tables)

Sales (Tables)	6 Months Ended
	Feb. 28, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes the Company’s sales by segment and by major source (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 U.S. Retail Pharmacy Pharmacy $ 19,874 $ 19,820 $ 40,092 $ 40,925 Retail 7,703 7,847 14,689 14,774 Total 27,577 27,667 54,781 55,699 International Pharmacy 898 958 1,766 1,975 Retail 1,994 1,880 3,643 3,676 Wholesale 2,759 2,725 5,431 5,730 Total 5,651 5,563 10,840 11,381 U.S. Healthcare 1,634 527 2,622 577 Corporate and Other 1 — (1) — (1) Walgreens Boots Alliance, Inc. $ 34,862 $ 33,756 $ 68,244 $ 67,656

Related parties (Tables)

Related parties (Tables)	6 Months Ended
	Feb. 28, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	Related party transactions with AmerisourceBergen (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Purchases, net $ 15,759 $ 15,063 $ 31,199 $ 30,854 February 28, 2023 August 31, 2022 Trade accounts payable, net of Trade accounts receivable $ 7,839 $ 6,915

Supplemental information (Table

Supplemental information (Tables)	6 Months Ended
	Feb. 28, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Depreciation and Amortization Expense	The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Depreciation expense $ 361 $ 348 $ 697 $ 683 Intangible assets amortization 199 175 357 340 Total depreciation and amortization expense $ 559 $ 524 $ 1,055 $ 1,024
Restrictions on Cash and Cash Equivalents	The following represents a reconciliation of Cash and cash equivalents in the Consolidated Condensed Balance Sheets to total Cash, cash equivalents, marketable securities and restricted cash in the Consolidated Condensed Statements of Cash Flows as of February 28, 2023 and August 31, 2022, respectively (in millions): February 28, 2023 August 31, 2022 Cash and cash equivalents $ 1,088 $ 1,358 Marketable securities 752 1,114 Restricted cash (included in other current and non-current assets) 153 86 Cash, cash equivalents, marketable securities and restricted cash $ 1,993 $ 2,558
Schedule of Redeemable Noncontrolling Interest	The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions): Three months ended February 28, Six months ended February 28, 2023 2022 2023 2022 Opening balance $ 157 $ 2,787 $ 1,042 $ 319 Recognition upon acquisition of subsidiary 1 — — — 2,489 Acquisition of non-controlling interests 2 — (2,047) — (2,047) Net loss attributable to Redeemable non-controlling interests (1) (12) (24) (33) Redemption price adjustments 3 — 83 440 90 Reclassifications to Accrued expenses and other liabilities 4 — — (1,314) — Other 3 2 14 (6) Ending balance $ 158 $ 812 $ 158 $ 812 1. The six months ended February 28, 2022, includes $1.9 billion of redeemable non-controlling interest, representing the maximum purchase price to redeem non-controlling units in VillageMD for cash, and redeemable non-controlling interest in Shields. On November 24, 2021, VillageMD commenced a tender offer to purchase up to $1.9 billion of units in VillageMD for cash. The tender offer was fully subscribed and settled on December 28, 2021. The tender offer was funded by cash proceeds provided to VillageMD pursuant to the Unit Purchase Agreement. 2. The three and six months ended February 28, 2022 includes, $1.9 billion paid to existing shareholders of VillageMD as part of the fully subscribed tender offer and the acquisition of the remaining 30% non-controlling equity interests in the pharmaceutical wholesale business in Germany. 3. Remeasurement of non-controlling interests, probable of redemption but not currently redeemable, to their redemption value, is recorded to Paid in capital in the Consolidated Condensed Balance Sheets. During the three months ended November 30, 2022, the Company announced the acceleration of its plans for full ownership of Shields and CareCentrix. The Shields and CareCentrix redeemable non-controlling interests were recorded to redemption value. 4. Represents the reclassification of the Shields and CareCentrix redeemable non-controlling interests to Accrued expenses and other liabilities, resulting from acceleration of the Company's plans for full ownership of Shields and CareCentrix. See Note 2. Acquisitions and other investments for further information.
Schedule of Dividends Payable	Cash dividends per common share declared were as follows: Quarter ended 2023 2022 November $ 0.4800 $ 0.4775 February $ 0.4800 $ 0.4775 Total $ 0.9600 $ 0.9550

Acquisitions and other invest_3

Acquisitions and other investments - Narrative (Details) - USD ($) $ in Millions

3 Months Ended

6 Months Ended

Jan. 03, 2023

Dec. 28, 2022

Oct. 11, 2022

Aug. 31, 2022

Nov. 24, 2021

Oct. 29, 2021

Feb. 28, 2023

Nov. 30, 2022

Feb. 28, 2022

Nov. 30, 2021

Feb. 28, 2023

Feb. 28, 2022

Nov. 23, 2021

Oct. 28, 2021

Business Acquisition [Line Items]

Gain on sale of equity method investments

$ 1,512

$ 0

Goodwill, purchase adjustments

252

VillageMD

Business Acquisition [Line Items]

Fair value of equity consideration

$ 1,750

Noncontrolling interest, ownership percentage by parent

53%

Debt instrument, fee amount, credit

$ 220

VillageMD | Line of Credit

Business Acquisition [Line Items]

Face amount

2,250

VillageMD | Line of Credit | Term Loan

Business Acquisition [Line Items]

Face amount

1,750

VillageMD | Line of Credit | Credit facilities

Business Acquisition [Line Items]

Face amount

500

VillageMD | Cigna

Business Acquisition [Line Items]

Fair value of equity consideration

2,500

VillageMD

Business Acquisition [Line Items]

Purchase price

$ 5,200

Fair value of equity consideration

683

Intangible assets

$ 1,621

Outstanding equity interest percentage

63%

30%

Cash consideration, gross

$ 4,000

Promissory note

1,200

Business combination, consideration transferred to existing stockholders

2,900

Value of purchase tender offer

1,900

Cash consideration for preferred units

1,100

Gain related to fair value of company's previously held minority equity interest

$ 1,597

Pre-tax gain related to conversion of previously held investment in convertible debt securities

577

Gain on sale of equity method investments

2,200

Goodwill, purchase adjustments

$ 125

VillageMD | Provider networks

Business Acquisition [Line Items]

Intangible assets

$ 1,200

Useful life of intangible assets

15 years

VillageMD | Trade Names

Business Acquisition [Line Items]

Intangible assets

$ 295

Useful life of intangible assets

13 years

VillageMD | Technology-Based Intangible Assets

Business Acquisition [Line Items]

Intangible assets

$ 76

Useful life of intangible assets

5 years

Shields Health Solutions Parent, LLC

Business Acquisition [Line Items]

Cash consideration, subject to purchase price adjustments

$ 969

Fair value of equity consideration

13

Intangible assets

$ 1,060

Outstanding equity interest percentage

30%

70%

25%

Cash consideration, gross

$ 1,400

Gain on sale of equity method investments

$ 402

Goodwill, purchase adjustments

$ 72

Shields Health Solutions Parent, LLC | Trade Names

Business Acquisition [Line Items]

Intangible assets

$ 47

Useful life of intangible assets

13 years

Shields Health Solutions Parent, LLC | Technology-Based Intangible Assets

Business Acquisition [Line Items]

Intangible assets

$ 117

Useful life of intangible assets

5 years

Shields Health Solutions Parent, LLC | Customer Relationships

Business Acquisition [Line Items]

Intangible assets

$ 896

Useful life of intangible assets

13 years

CareCentrix, Inc

Business Acquisition [Line Items]

Cash consideration, subject to purchase price adjustments

$ 327

Purchase price

$ 392

Fair value of equity consideration

66

Business combination, consideration transferred, employees

12

Intangible assets

$ 426

Outstanding equity interest percentage

45%

55%

Cash consideration, gross

$ 339

Goodwill, purchase adjustments

$ (6)

56

CareCentrix, Inc | Trade Names

Business Acquisition [Line Items]

Intangible assets

$ 93

Useful life of intangible assets

13 years

CareCentrix, Inc | Technology-Based Intangible Assets

Business Acquisition [Line Items]

Intangible assets

$ 86

Useful life of intangible assets

5 years

CareCentrix, Inc | Customer Relationships

Business Acquisition [Line Items]

Intangible assets

$ 247

Useful life of intangible assets

13 years

Other Acquisitions

Business Acquisition [Line Items]

Cash consideration, net

$ 35

$ 42

$ 90

$ 116

Summit Health-CityMD

Business Acquisition [Line Items]

Cash consideration, subject to purchase price adjustments

7,000

Purchase price

4,850

Fair value of equity consideration

1,980

Deferred consideration

100

Business combination, consideration transferred, employees

86

Summit debt paid at closing

1,900

Intangible assets

3,359

Summit Health-CityMD | Preferred Partnership Interest

Business Acquisition [Line Items]

Fair value of equity consideration

2,050

Summit Health-CityMD | Provider networks

Business Acquisition [Line Items]

Intangible assets

$ 1,900

Useful life of intangible assets

16 years

Summit Health-CityMD | Trade Names

Business Acquisition [Line Items]

Intangible assets

$ 1,500

Summit Health-CityMD | Minimum | Trade Names

Business Acquisition [Line Items]

Useful life of intangible assets

11 years

Summit Health-CityMD | Maximum | Trade Names

Business Acquisition [Line Items]

Useful life of intangible assets

15 years

Acquisitions and other invest_4

Acquisitions and other investments - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed - Summit (Details) - USD ($) $ in Millions	Jan. 03, 2023	Feb. 28, 2023	Aug. 31, 2022
Identifiable assets acquired and liabilities assumed:
Goodwill		$ 28,343	$ 22,280
Summit Health-CityMD
Purchase Price Allocation:
Purchase price	$ 4,790
Deferred consideration	100
Summit debt paid at closing	1,963
Fair value of equity consideration	1,980
Total	8,833
Identifiable assets acquired and liabilities assumed:
Cash and cash equivalents	75
Accounts receivable, net	361
Property, plant and equipment	593
Intangible assets	3,359
Operating lease right-of-use assets	757
Other assets	192
Operating lease obligations	(773)
Deferred tax liability	(918)
Other liabilities	(507)
Total identifiable net assets	3,139
Goodwill	$ 5,693

Acquisitions and other invest_5

Acquisitions and other investments - Schedule of Pro Forma and Actual Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Summit Health-CityMD
Business Acquisition [Line Items]
Sales, pro forma	$ 35,119	$ 34,402	$ 69,216	$ 68,924
Sales, actual	$ 463		$ 463
VillageMD, Shields And CareCentrix
Business Acquisition [Line Items]
Sales, pro forma		34,063		68,627
Sales, actual		$ 527		$ 577

Acquisitions and other invest_6

Acquisitions and other investments - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed - Village MD (Details) - USD ($) $ in Millions	Nov. 24, 2021	Feb. 28, 2023	Aug. 31, 2022
Identifiable assets acquired and liabilities assumed:
Goodwill		$ 28,343	$ 22,280
VillageMD
Purchase Price Allocation:
Total purchase price	$ 5,200
Less: purchase price for issuance of new preferred units at fair value	(2,300)
Net consideration	2,900
Fair value of equity consideration	683
Fair value of previously held equity interests	3,211
Fair value of non-controlling interests	3,257
Total	10,051
Identifiable assets acquired and liabilities assumed:
Tangible assets	634
Intangible assets	1,621
Liabilities	(370)
Total identifiable net assets	1,885
Goodwill	$ 8,166

Acquisitions and other invest_7

Acquisitions and other investments - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed - Shields (Details) - USD ($) $ in Millions	Oct. 29, 2021	Feb. 28, 2023	Aug. 31, 2022
Identifiable assets acquired and liabilities assumed:
Goodwill		$ 28,343	$ 22,280
Shields Health Solutions Parent, LLC
Purchase Price Allocation:
Cash consideration	$ 969
Fair value of equity consideration	13
Fair value of previously held equity interests	502
Fair value of non-controlling interests	589
Total	2,074
Identifiable assets acquired and liabilities assumed:
Tangible assets	84
Intangible assets	1,060
Liabilities	(600)
Total identifiable net assets	544
Goodwill	$ 1,529

Acquisitions and other invest_8

Acquisitions and other investments - Schedule of Purchase Price Allocation and Identifiable Assets Acquired and Liabilities Assumed - CareCentrix (Details) - USD ($) $ in Millions	Aug. 31, 2022	Feb. 28, 2023
Identifiable assets acquired and liabilities assumed:
Goodwill	$ 22,280	$ 28,343
CareCentrix, Inc
Purchase Price Allocation:
Cash consideration	327
Contingent consideration	4
Fair value of equity consideration	66
Fair value of non-controlling interests	217
Total	614
Identifiable assets acquired and liabilities assumed:
Tangible assets	358
Intangible assets	426
Liabilities	(680)
Total identifiable net assets	104
Goodwill	$ 509

Exit and disposal activities -

Exit and disposal activities - Narrative (Details) $ in Millions			6 Months Ended
	Oct. 12, 2021 USD ($) store	Dec. 20, 2018 USD ($)	Feb. 28, 2023 USD ($) store	Feb. 28, 2022 USD ($)	Nov. 30, 2022 USD ($)	Aug. 31, 2022 USD ($)	Nov. 30, 2021 USD ($)	Aug. 31, 2021 USD ($)	Sep. 01, 2019 USD ($)
Restructuring Cost and Reserve [Line Items]
Cumulative effect adjustment to decrease retained earnings			$ (29,439)	$ (30,867)	$ (24,582)	$ (29,366)	$ (30,579)	$ (23,822)
Retained Earnings
Restructuring Cost and Reserve [Line Items]
Cumulative effect adjustment to decrease retained earnings			(33,952)	(38,757)	$ (33,664)	$ (37,801)	$ (38,286)	$ (35,121)
Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			$ 2,200
Transformational Cost Management Program | United Kingdom
Restructuring Cost and Reserve [Line Items]
Number of stores expected to close | store	350
Number of stores closed | store			252
Transformational Cost Management Program | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Number of stores closed | store			403
Transformational Cost Management Program | Retained Earnings | Adoption of New Accounting Standards
Restructuring Cost and Reserve [Line Items]
Cumulative effect adjustment to decrease retained earnings									$ 508
Lease Obligations and Other Real Estate Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			$ 700
Asset Impairments | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			556
Employee Severance and Business Transition Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			754
Information Technology Transformation and Other Exit Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			228
Minimum | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected annual cost savings of restructuring plan	$ 3,300	$ 2,000
Expected cost			3,600
Minimum | Transformational Cost Management Program | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Number of stores expected to close | store	450
Minimum | Exit and Disposal Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected cost			3,300
Maximum | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected annual cost savings of restructuring plan				$ 3,500
Expected cost			3,900
Maximum | Transformational Cost Management Program | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Number of stores expected to close | store	500
Maximum | Exit and Disposal Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected cost			$ 3,600

Exit and disposal activities _2

Exit and disposal activities - Restructuring Costs (Details) - Transformational Cost Management Program - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	$ 138	$ 56	$ 267	$ 231
Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	131	43	250	166
Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	4	8	10	51
Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	2	5	6	14
Lease obligations and other real estate costs
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	20	5	98	95
Lease obligations and other real estate costs | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	20	5	98	91
Lease obligations and other real estate costs | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	0	1	0	3
Lease obligations and other real estate costs | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	0	0	0	0
Asset impairments
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	95	4	113	44
Asset impairments | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	96	1	115	16
Asset impairments | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	(1)	3	(1)	28
Asset impairments | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	0	0	0	0
Employee severance and business transition costs
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	15	41	31	79
Employee severance and business transition costs | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	11	36	22	56
Employee severance and business transition costs | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	1	0	2	9
Employee severance and business transition costs | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	3	5	7	14
Information technology transformation and other exit costs
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	9	5	25	13
Information technology transformation and other exit costs | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	4	1	16	2
Information technology transformation and other exit costs | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	5	4	10	11
Information technology transformation and other exit costs | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total exit and disposal charges	$ (1)	$ 0	$ (1)	$ 0

Exit and disposal activities _3

Exit and disposal activities - Restructuring Reserve Activity (Details) - Transformational Cost Management Program $ in Millions	6 Months Ended
	Feb. 28, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 113
Costs	267
Payments	(139)
Other	(170)
Ending balance	72
Lease obligations and other real estate costs
Restructuring Reserve [Roll Forward]
Beginning balance	10
Costs	98
Payments	(51)
Other	(57)
Ending balance	0
Asset Impairments
Restructuring Reserve [Roll Forward]
Beginning balance	0
Costs	113
Payments	0
Other	(113)
Ending balance	0
Employee severance and business transition costs
Restructuring Reserve [Roll Forward]
Beginning balance	76
Costs	31
Payments	(72)
Other	1
Ending balance	36
Information technology transformation and other exit costs
Restructuring Reserve [Roll Forward]
Beginning balance	27
Costs	25
Payments	(17)
Other	0
Ending balance	$ 36

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	Feb. 28, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Term of renewal contract	5 years
Undiscounted minimum lease payments, payments associated with options to extend lease terms	$ 3,500
Lessor, operating lease, payments to be received	$ 600
Minimum
Lessee, Lease, Description [Line Items]
Term of lease	15 years
Maximum
Lessee, Lease, Description [Line Items]
Term of lease	25 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	Feb. 28, 2023	Aug. 31, 2022
Operating Leases:
Operating lease right-of-use assets	$ 22,024	$ 21,259
Operating lease obligations - current	2,340	2,286
Operating lease obligations - non-current	22,195	21,517
Total operating lease obligations	24,534	23,803
Finance leases:
Property, plant and equipment, net	694	645
Lease obligations included in:
Accrued expenses and other liabilities	53	37
Other non-current liabilities	931	899
Total finance lease obligations	$ 984	$ 936
Finance lease, right-of-use asset, statement of financial position, extensible enumeration	Property, plant and equipment, net	Property, plant and equipment, net
Finance lease, liability, current, statement of financial position, extensible enumeration	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Finance lease, liability, noncurrent, statement of financial position, extensible enumeration	Other non-current liabilities	Other non-current liabilities

Leases - Supplemental Income St

Leases - Supplemental Income Statement Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Operating lease cost
Fixed	$ 853	$ 815	$ 1,667	$ 1,619
Variable	203	197	395	402
Finance lease cost
Amortization	11	11	21	22
Interest	12	13	24	26
Sublease income	28	26	57	51
Impairment of right-of-use assets	4	3	71	71
Gain on sale and leaseback	343	148	532	235
U.S. Retail Pharmacy
Finance lease cost
Gain on sale and leaseback	211	148	384	235
International
Finance lease cost
Gain on sale and leaseback	132	$ 0	148	$ 0
International | GERMANY
Finance lease cost
Gain on sale and leaseback	132		148
International | GERMANY | Fiscal Year 2023 Acquistions
Finance lease cost
Gain on sale and leaseback	$ 24		$ 41

Leases - Other Supplemental Inf

Leases - Other Supplemental Information (Details) - USD ($) $ in Millions	6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022
Cash paid for amounts included in the measurement of lease obligations
Operating cash flows from operating leases	$ 1,720	$ 1,666
Operating cash flows from finance leases	22	23
Financing cash flows from finance leases	21	21
Total	1,763	1,710
Right-of-use assets obtained in exchange for new lease obligations
Operating leases	1,135	1,005
Finance leases	18	11
Total	$ 1,154	$ 1,016

Leases - Average Lease Terms An

Leases - Average Lease Terms And Discounts (Details)	Feb. 28, 2023	Aug. 31, 2022
Weighted average remaining lease term in years
Operating leases	9 years 9 months 18 days	10 years
Finance leases	17 years 8 months 12 days	19 years
Weighted average discount rate
Operating leases	5.26%	4.83%
Finance leases	5.26%	5.19%

Leases - Future Lease Payments

Leases - Future Lease Payments for Operating and Finance Leases (Details) - USD ($) $ in Millions	Feb. 28, 2023	Aug. 31, 2022
Finance lease
2023 (Remaining period)	$ 53
2024	105
2025	101
2026	98
2027	97
2028	88
Later	958
Total undiscounted minimum lease payments	1,501
Less: Present value discount	516
Lease liability	984	$ 936
Operating lease
2023 (Remaining period)	1,805
2024	3,555
2025	3,450
2026	3,361
2027	3,266
2028	3,108
Later	12,980
Total undiscounted minimum lease payments	31,524
Less: Present value discount	6,990
Lease liability	$ 24,534	$ 23,803

Equity method investments - Sch

Equity method investments - Schedule of Equity Method Investments (Details) - USD ($) $ in Millions	Feb. 28, 2023	Aug. 31, 2022
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 4,069	$ 5,495
AmerisourceBergen
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 2,563	$ 3,916
Ownership percentage	16.70%	25.40%
Others
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 1,506	$ 1,579
Others | Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	4%	8%
Others | Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	50%	50%
Total
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 4,069	$ 5,495

Equity method investments - Nar

Equity method investments - Narrative (Details) - USD ($) shares in Millions, $ in Millions					3 Months Ended		6 Months Ended
	Mar. 03, 2023	Dec. 15, 2022	Dec. 13, 2022	Nov. 10, 2022	Feb. 28, 2023	Nov. 30, 2021	Feb. 28, 2023	Feb. 28, 2022	Aug. 31, 2022
Schedule of Equity Method Investments [Line Items]
Gain on sale of equity method investments							$ 1,512	$ 0
Impairment of equity method investments and investments in equity securities							$ 8	$ 190
Shields Health Solutions Parent, LLC
Schedule of Equity Method Investments [Line Items]
Gain on sale of equity method investments						$ 402
VillageMD
Schedule of Equity Method Investments [Line Items]
Gain on sale of equity method investments						$ 2,200
Impairment of equity method investments and investments in equity securities					$ 124
AmerisourceBergen
Schedule of Equity Method Investments [Line Items]
Outstanding shares owned (in shares)					33.7		33.7		52.9
Ownership percentage					16.70%		16.70%		25.40%
Number of shares sold (in shares)			6	13.2
Proceeds from sale of equity method investments			$ 984	$ 2,000
Gain on sale of equity method investments			492	969
Other comprehensive (loss) income before reclassification adjustments			$ 40	$ (110)
Period of reporting lag							2 months
Equity investment, exceeded its proportionate share of net assets					$ 2,600		$ 2,600
AmerisourceBergen | Level 1
Schedule of Equity Method Investments [Line Items]
Fair market value of equity investment					$ 5,200		$ 5,200		$ 7,700
Guangzhou Pharmaceuticals
Schedule of Equity Method Investments [Line Items]
Proceeds from sale of equity method investments		$ 150
Option Care Health
Schedule of Equity Method Investments [Line Items]
Percentage of outstanding common stock					14.40%		14.40%
Option Care Health | Subsequent Event
Schedule of Equity Method Investments [Line Items]
Number of shares sold (in shares)	13
Proceeds from sale of equity method investments	$ 469
Percentage of outstanding common stock	6%
Option Care Health | Subsequent Event | Option Care Health
Schedule of Equity Method Investments [Line Items]
Share repurchase option (in shares)	2.5

Goodwill and other intangible_3

Goodwill and other intangible assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022	Aug. 31, 2022	Jun. 01, 2022	Jun. 01, 2021
Goodwill [Line Items]
Goodwill	$ 28,343		$ 28,343		$ 22,280
Indefinite-lived intangible assets	5,628		5,628		5,528
Amortization of intangible assets	199	$ 175	357	$ 340
Minimum
Goodwill [Line Items]
Reporting unit fair value in excess of carrying amount (as a percent)						7%	7%
Maximum
Goodwill [Line Items]
Reporting unit fair value in excess of carrying amount (as a percent)						198%	18%
Boots Reporting Unit
Goodwill [Line Items]
Goodwill	940		940		906
Indefinite-lived intangible assets	$ 5,600		$ 5,600		$ 5,500

Goodwill and other intangible_4

Goodwill and other intangible assets - Schedule of Goodwill (Details) $ in Millions	6 Months Ended
	Feb. 28, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 22,280
Acquisitions	5,735
Adjustments	252
Currency translation adjustments	76
Goodwill, ending balance	28,343
Reportable Segments | U.S. Retail Pharmacy
Goodwill [Roll Forward]
Goodwill, beginning balance	10,947
Acquisitions	0
Adjustments	0
Currency translation adjustments	0
Goodwill, ending balance	10,947
Reportable Segments | International
Goodwill [Roll Forward]
Goodwill, beginning balance	1,293
Acquisitions	0
Adjustments	0
Currency translation adjustments	76
Goodwill, ending balance	1,369
Reportable Segments | U.S. Healthcare
Goodwill [Roll Forward]
Goodwill, beginning balance	10,040
Acquisitions	5,735
Adjustments	252
Currency translation adjustments	0
Goodwill, ending balance	$ 16,027

Goodwill and other intangible_5

Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details) - USD ($) $ in Millions	Feb. 28, 2023	Aug. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	$ 10,373	$ 7,155
Accumulated amortization	2,136	1,953
Total amortizable intangible assets, net	8,237	5,202
Indefinite-lived intangible assets	5,628	5,528
Total intangible assets, net	13,864	10,730
Trade names and trademarks
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	4,397	4,319
Pharmacy licenses
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	1,231	1,209
Customer relationships and loyalty card holders
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	4,466	4,619
Accumulated amortization	1,574	1,548
Provider networks
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	3,099	1,247
Accumulated amortization	126	64
Trade names and trademarks
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	2,271	760
Accumulated amortization	301	246
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	442	436
Accumulated amortization	92	56
Others
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	95	93
Accumulated amortization	$ 43	$ 39

Goodwill and other intangible_6

Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Millions	Feb. 28, 2023 USD ($)
Estimated annual intangible assets amortization expense [Abstract]
2023 (Remaining period)	$ 431
2024	846
2024	814
2025	796
2027	733
2027	$ 674

Debt - Short and Long-Term Debt

Debt - Short and Long-Term Debt (Details)	6 Months Ended
	Feb. 28, 2023 USD ($)	Feb. 28, 2023 GBP (£)	Feb. 28, 2023 EUR (€)	Aug. 31, 2022 USD ($)	Nov. 17, 2021 USD ($)
Debt Instrument [Line Items]
Total short-term debt	$ 4,222,000,000			$ 1,059,000,000
Total long-term debt, less current portion	8,820,000,000			10,615,000,000
Other
Debt Instrument [Line Items]
Total short-term debt	$ 79,000,000			59,000,000
Credit facilities | Unsecured credit facility, 2 year term, due 2023
Debt Instrument [Line Items]
Debt term	2 years
Long-term debt	$ 0			1,998,000,000
Credit facilities | Unsecured credit facility, 3 year term, due 2024
Debt Instrument [Line Items]
Debt term	3 years
Long-term debt	$ 999,000,000			999,000,000
Credit facilities | Unsecured Credit Facility, 3 Year Term, Due 2026
Debt Instrument [Line Items]
Debt term	3 years
Long-term debt	$ 999,000,000			0
Unsecured Notes
Debt Instrument [Line Items]
Other	23,000,000			26,000,000
Total long-term debt, less current portion	8,820,000,000			10,615,000,000
Unsecured Notes | 0.9500% Notes Payable, Due 2023
Debt Instrument [Line Items]
Face amount					$ 850,000,000
Stated interest rate					0.95%
Long-term debt	0			848,000,000
Unsecured Notes | Total $1.5 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 1,500,000,000
Unsecured Notes | 3.200% unsecured notes due 2030
Debt Instrument [Line Items]
Stated interest rate	3.20%	3.20%	3.20%
Long-term debt	$ 498,000,000			498,000,000
Unsecured Notes | 4.100% unsecured notes due 2050
Debt Instrument [Line Items]
Stated interest rate	4.10%	4.10%	4.10%
Long-term debt	$ 792,000,000			792,000,000
Unsecured Notes | Total $6 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 6,000,000,000
Unsecured Notes | 3.450% unsecured notes due 2026
Debt Instrument [Line Items]
Stated interest rate	3.45%	3.45%	3.45%
Long-term debt	$ 1,443,000,000			1,443,000,000
Unsecured Notes | 4.650% unsecured notes due 2046
Debt Instrument [Line Items]
Stated interest rate	4.65%	4.65%	4.65%
Long-term debt	$ 318,000,000			318,000,000
Unsecured Notes | Total $8 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 8,000,000,000
Unsecured Notes | 3.800% unsecured notes due 2024
Debt Instrument [Line Items]
Stated interest rate	3.80%	3.80%	3.80%
Long-term debt	$ 1,155,000,000			1,155,000,000
Unsecured Notes | 4.500% unsecured notes due 2034
Debt Instrument [Line Items]
Stated interest rate	4.50%	4.50%	4.50%
Long-term debt	$ 301,000,000			301,000,000
Unsecured Notes | 4.800% unsecured notes due 2044
Debt Instrument [Line Items]
Stated interest rate	4.80%	4.80%	4.80%
Long-term debt	$ 869,000,000			869,000,000
Unsecured Notes | Total £700 million note issuance
Debt Instrument [Line Items]
Face amount | £		£ 700,000,000
Unsecured Notes | 3.600% unsecured pound sterling notes due 2025
Debt Instrument [Line Items]
Stated interest rate	3.60%	3.60%	3.60%
Long-term debt	$ 361,000,000			354,000,000
Unsecured Notes | Total €750 million note issuance
Debt Instrument [Line Items]
Face amount | €			€ 750,000,000
Unsecured Notes | 2.125% unsecured euro notes due 2026
Debt Instrument [Line Items]
Stated interest rate	2.125%	2.125%	2.125%
Long-term debt	$ 799,000,000			752,000,000
Unsecured Notes | Total $4 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 4,000,000,000
Unsecured Notes | 4.400% unsecured notes due 2042
Debt Instrument [Line Items]
Stated interest rate	4.40%	4.40%	4.40%
Long-term debt	$ 263,000,000			263,000,000
Commercial paper
Debt Instrument [Line Items]
Total short-term debt	$ 1,296,000,000			0
Credit facilities | Unsecured credit facility, 364 day term, due 2023
Debt Instrument [Line Items]
Debt term	364 days
Total short-term debt	$ 0			1,000,000,000
Credit facilities | Unsecured credit facility, 2 year term, due 2023
Debt Instrument [Line Items]
Debt term	2 years
Total short-term debt	$ 1,999,000,000			0
Unsecured Notes | $850 million note issuance
Debt Instrument [Line Items]
Face amount	850,000,000
Unsecured Notes | 0.9500% Notes Payable, Due 2023
Debt Instrument [Line Items]
Total short-term debt	$ 849,000,000			$ 0
Stated interest rate	0.95%	0.95%	0.95%

Debt - Narrative (Details)

Debt - Narrative (Details) $ in Millions				6 Months Ended
	Jun. 17, 2022 USD ($)	Nov. 17, 2021 USD ($)	Nov. 15, 2021 USD ($)	Feb. 28, 2023 USD ($)	Feb. 28, 2022 USD ($)	Dec. 19, 2022 USD ($)	Aug. 31, 2022 USD ($)
Debt Instrument [Line Items]
Interest paid				$ 288	$ 211
Maximum
Debt Instrument [Line Items]
Debt to total capitalization ratio				0.60
Commercial paper
Debt Instrument [Line Items]
Average daily short-term borrowings				$ 1,000	$ 1,100
Weighted average interest rate				5.04%	0.33%
Unsecured Notes | 0.9500% Notes Payable, Due 2023
Debt Instrument [Line Items]
Face amount		$ 850
Stated interest rate		0.95%
Redemption percentage		100%
Amount outstanding				$ 0			$ 848
Unsecured Credit Facility, 3 Year Term, Due 2026 | Credit facilities
Debt Instrument [Line Items]
Face amount						$ 1,000
Borrowing outstanding				1,000
Credit facilities | June 17, 2022 Revolving Credit Facility, Five-Year Term
Debt Instrument [Line Items]
Face amount	$ 3,500
Debt term	5 years
Credit facilities | June 17, 2022 Revolving Credit Facility, 18-Month Facility
Debt Instrument [Line Items]
Face amount	$ 1,500
Borrowing outstanding				0
Debt term	18 months
Credit facilities | June 17, 2022 Revolving Credit Facility, 18-Month Facility | Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.50%
Credit facilities | June 17, 2022 Revolving Credit Facility, 18-Month Facility | Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.80%
Credit facilities | Delayed Draw Term Loan | Term Loan
Debt Instrument [Line Items]
Face amount			$ 5,000
Amount outstanding				$ 3,000
Credit facilities | Delayed Draw Term Loan Credit Facility, 364-Day Facility | Term Loan
Debt Instrument [Line Items]
Face amount			$ 2,000
Debt term			364 days
Credit facilities | Delayed Draw Term Loan Credit Facility, 364-Day Facility | Term Loan | Eurodollar
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate			0.75%
Credit facilities | Delayed Draw Term Loan Credit Facility, Two-Year Facility
Debt Instrument [Line Items]
Face amount			$ 2,000
Credit facilities | Delayed Draw Term Loan Credit Facility, Two-Year Facility | Term Loan
Debt Instrument [Line Items]
Debt term			2 years
Credit facilities | Delayed Draw Term Loan Credit Facility, Two-Year Facility | Term Loan | Eurodollar
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate			0.85%
Credit facilities | Delayed Draw Term Loan Credit Facility, Three-Year Facility
Debt Instrument [Line Items]
Face amount			$ 1,000
Credit facilities | Delayed Draw Term Loan Credit Facility, Three-Year Facility | Term Loan
Debt Instrument [Line Items]
Debt term			3 years
Credit facilities | Term Loan
Debt Instrument [Line Items]
Face amount			$ 3,000
Credit facilities | Term Loan | June 17, 2022 Revolving Credit Facility, Five-Year Term
Debt Instrument [Line Items]
Debt term	5 years
Credit facilities | Term Loan | June 17, 2022 Revolving Credit Facility, 18-Month Facility
Debt Instrument [Line Items]
Debt term	18 years
Credit facilities | Term Loan | Delayed Draw Term Loan Credit Facility, Three-Year Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate			1%

Financial instruments (Details)

Financial instruments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022	Aug. 31, 2022
Foreign currency forwards | Not Designated as Hedging Instrument | Selling, general and administrative expense
Derivatives, Fair Value [Line Items]
Gains and (losses) due to changes in fair value of derivative instruments	$ 0	$ (51)	$ 0	$ 4
Foreign currency forwards | Not Designated as Hedging Instrument | Other income, net
Derivatives, Fair Value [Line Items]
Gains and (losses) due to changes in fair value of derivative instruments	(73)	0	(92)	(1)
Total return swap | Not Designated as Hedging Instrument | Selling, general and administrative expense
Derivatives, Fair Value [Line Items]
Gains and (losses) due to changes in fair value of derivative instruments	(3)	$ (8)	0	$ (10)
Other current assets | Foreign currency forwards | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	319		319		$ 448
Fair value, assets	6		6		19
Other current assets | Foreign currency forwards | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	1,831		1,831		2,874
Fair value, assets	20		20		49
Other current assets | Cross currency interest rate swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	100		100		150
Fair value, assets	3		3		12
Other non-current assets | Foreign currency forwards | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	8		8		3
Fair value, assets	0		0		0
Other non-current assets | Cross currency interest rate swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	650		650		750
Fair value, assets	55		55		83
Other current liabilities | Foreign currency forwards | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	470		470		221
Fair value, liabilities	4		4		1
Other current liabilities | Foreign currency forwards | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	2,065		2,065		1,098
Fair value, liabilities	48		48		6
Other current liabilities | Total return swap | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	217		217		183
Fair value, liabilities	8		8		$ 6
Other non-current liabilities | Foreign currency forwards | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	4		4
Fair value, liabilities	$ 0		$ 0

Fair value measurements (Detail

Fair value measurements (Details) - USD ($) $ in Millions	Feb. 28, 2023	Aug. 31, 2022
Carrying Value
Liabilities [Abstract]
Fair value of long-term notes outstanding	$ 7,600
Estimate of Fair Value Measurement
Liabilities [Abstract]
Carrying value of long-term notes outstanding	6,800
Recurring
Assets [Abstract]
Money market funds	752	$ 1,114
Investments in equity securities		1
Investments in debt securities		130
Level 1 | Recurring
Assets [Abstract]
Money market funds	752	1,114
Investments in equity securities		1
Investments in debt securities		0
Level 2 | Recurring
Assets [Abstract]
Money market funds	0	0
Investments in equity securities		0
Investments in debt securities		130
Level 3 | Recurring
Assets [Abstract]
Money market funds	0	0
Investments in equity securities		0
Investments in debt securities		0
Foreign currency forwards | Recurring
Assets [Abstract]
Derivative asset	27	69
Liabilities [Abstract]
Derivative liability	52	7
Foreign currency forwards | Level 1 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability	0	0
Foreign currency forwards | Level 2 | Recurring
Assets [Abstract]
Derivative asset	27	69
Liabilities [Abstract]
Derivative liability	52	7
Foreign currency forwards | Level 3 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability	0	0
Cross currency interest rate swaps | Recurring
Assets [Abstract]
Derivative asset	58	96
Cross currency interest rate swaps | Level 1 | Recurring
Assets [Abstract]
Derivative asset	0	0
Cross currency interest rate swaps | Level 2 | Recurring
Assets [Abstract]
Derivative asset	58	96
Cross currency interest rate swaps | Level 3 | Recurring
Assets [Abstract]
Derivative asset	0	0
Total return swap | Recurring
Liabilities [Abstract]
Derivative liability	8	6
Total return swap | Level 1 | Recurring
Liabilities [Abstract]
Derivative liability	0	0
Total return swap | Level 2 | Recurring
Liabilities [Abstract]
Derivative liability	8	6
Total return swap | Level 3 | Recurring
Liabilities [Abstract]
Derivative liability	$ 0	$ 0

Commitment and contingencies (D

Commitment and contingencies (Details) - USD ($) $ in Millions				1 Months Ended
	Nov. 02, 2022	Jun. 29, 2022	May 05, 2022	Aug. 31, 2022	Feb. 28, 2023	Nov. 30, 2022
Loss Contingencies [Line Items]
Accrued litigation obligations				$ 551	$ 6,365
Washtenaw County Employees Retirement System | Settled Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party		$ 105
Settlement Frameworks | Pending Litigation
Loss Contingencies [Line Items]
Litigation settlement, period	6 years
Accrued litigation obligations	$ 754
Estimated litigation liability						$ 6,500
Settlement Frameworks | Settled Litigation
Loss Contingencies [Line Items]
Accrued litigation obligations					6,400
Estimated litigation liability, current					1,000
Estimated litigation liability					$ 7,400
Settling States | Pending Litigation
Loss Contingencies [Line Items]
Litigation settlement, period	15 years
Estimated litigation liability	$ 4,800
Settling Tribes | Pending Litigation
Loss Contingencies [Line Items]
Litigation settlement, period	15 years
Estimated litigation liability	$ 155
Consolidated Cases in State of Florida | Settled Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party			$ 683
Litigation settlement, period			18 years
Accrued litigation obligations			$ 620
Estimated litigation liability, current			$ 63
Estimated litigation liability				683
Ohio Combined Cases | Pending Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party				$ 650.6
Litigation settlement, period				15 years

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	11.50%	18.20%	29.50%	9.40%
Income taxes paid			$ 131	$ 201

Retirement benefits (Details)

Retirement benefits (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Components of net periodic benefit costs [Abstract]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (expense), net		Other income (expense), net
Interest costs	$ 63	$ 38	$ 122	$ 78
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (expense), net		Other income (expense), net
Expected returns on plan assets/other	$ (80)	(72)	$ (156)	(146)
Total net periodic pension income	(16)	(33)	(32)	(65)
Employer cash contributions to defined benefit pension plans			11
Expected employer cash contributions to defined benefit plan in current fiscal year	25		25
Selling, general and administrative expense
Components of net periodic benefit costs [Abstract]
Service costs	1	1	2	3
U.S. Retail Pharmacy
Components of net periodic benefit costs [Abstract]
Profit sharing provision expense	60	54	125	123
Foreign Plan
Components of net periodic benefit costs [Abstract]
Cost recognized in the consolidated condensed statements of earnings	$ 21	$ 23	$ 41	$ 48

Accumulated other comprehensi_3

Accumulated other comprehensive income (loss) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 24,582	$ 30,579	$ 29,366	$ 23,822
Net change in other comprehensive (loss) income	164	(24)	153	(220)
Ending balance	29,439	30,867	29,439	30,867
Pension/ post- retirement obligations
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(162)	(364)	(157)	(359)
Other comprehensive (loss) income before reclassification adjustments	0	1	0	0
Amounts reclassified from AOCI	(7)	(5)	(13)	(11)
Other		(6)		(6)
Tax benefit (provision)	2	2	3	3
Net change in other comprehensive (loss) income	(5)	(8)	(10)	(13)
Ending balance	(167)	(372)	(167)	(372)
Unrealized loss on cash flow hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(5)	(9)	(3)	(10)
Other comprehensive (loss) income before reclassification adjustments	(1)	0	(3)	0
Amounts reclassified from AOCI	1	1	0	1
Other		0		0
Tax benefit (provision)	0	0	0	(1)
Net change in other comprehensive (loss) income	0	0	(2)	1
Ending balance	(5)	(9)	(5)	(9)
Net investment hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	183	9	213	(35)
Other comprehensive (loss) income before reclassification adjustments	(57)	(22)	(96)	31
Amounts reclassified from AOCI	0	0	0	0
Other		0		0
Tax benefit (provision)	14	2	23	(8)
Net change in other comprehensive (loss) income	(43)	(20)	(73)	24
Ending balance	140	(11)	140	(11)
Unrealized gain (loss) on available for sale securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	1		1	96
Other comprehensive (loss) income before reclassification adjustments	(1)		(1)	450
Amounts reclassified from AOCI	0		0	(577)
Other				0
Tax benefit (provision)	0		0	31
Net change in other comprehensive (loss) income	(1)		(1)	(96)
Ending balance	0	0	0	0
Share of OCI of equity method investments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(250)	(74)	(254)	(29)
Other comprehensive (loss) income before reclassification adjustments	78	(105)	(25)	(165)
Amounts reclassified from AOCI	40	0	150	0
Other		0		0
Tax benefit (provision)	(30)	26	(33)	40
Net change in other comprehensive (loss) income	88	(80)	92	(125)
Ending balance	(162)	(154)	(162)	(154)
Cumulative translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(2,583)	(1,863)	(2,605)	(1,772)
Other comprehensive (loss) income before reclassification adjustments	133	78	158	(9)
Amounts reclassified from AOCI	(11)	3	(14)	(1)
Other		0		0
Tax benefit (provision)	0	0	0	0
Net change in other comprehensive (loss) income	122	81	144	(10)
Ending balance	(2,461)	(1,782)	(2,461)	(1,782)
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(2,815)	(2,301)	(2,805)	(2,109)
Other comprehensive (loss) income before reclassification adjustments	153	(48)	33	307
Amounts reclassified from AOCI	22	(1)	123	(587)
Other		(6)		(6)
Tax benefit (provision)	(15)	29	(6)	66
Net change in other comprehensive (loss) income	161	(26)	151	(220)
Ending balance	$ (2,654)	$ (2,328)	$ (2,654)	$ (2,328)

Segment reporting (Details)

Segment reporting (Details) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023 USD ($)	Feb. 28, 2022 USD ($)	Feb. 28, 2023 USD ($) segment	Feb. 28, 2022 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			3
Segment Reporting Information [Line Items]
Sales	$ 34,862	$ 33,756	$ 68,244	$ 67,656
Adjusted operating income (Non-GAAP measure)	1,215	1,657	2,229	3,434
Certain legal and regulatory accruals and settlements	(427)	0	(6,981)	0
Acquisition-related amortization	(247)	(250)	(577)	(415)
Acquisition-related costs	(148)	(44)	(187)	(115)
Transformational cost management	(145)	(70)	(283)	(273)
Adjustments to equity earnings in AmerisourceBergen	(31)	(51)	(117)	(94)
LIFO provision	(20)	5	(38)	(9)
Operating income (loss)	197	1,246	(5,954)	2,529
Reportable Segments | U.S. Retail Pharmacy
Segment Reporting Information [Line Items]
Sales	27,577	27,667	54,781	55,699
Adjusted operating income (Non-GAAP measure)	1,067	1,588	2,172	3,277
Reportable Segments | International
Segment Reporting Information [Line Items]
Sales	5,651	5,563	10,840	11,381
Adjusted operating income (Non-GAAP measure)	352	226	468	389
Reportable Segments | U.S. Healthcare
Segment Reporting Information [Line Items]
Sales	1,634	527	2,622	577
Adjusted operating income (Non-GAAP measure)	(159)	(77)	(311)	(90)
Corporate and Other
Segment Reporting Information [Line Items]
Sales	0	(1)	0	(1)
Adjusted operating income (Non-GAAP measure)	$ (44)	$ (79)	$ (100)	$ (143)

Sales (Details)

Sales (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Disaggregation of Revenue [Line Items]
Sales	$ 34,862	$ 33,756	$ 68,244	$ 67,656
Reportable Segments | U.S. Retail Pharmacy
Disaggregation of Revenue [Line Items]
Sales	27,577	27,667	54,781	55,699
Reportable Segments | U.S. Retail Pharmacy | Pharmacy
Disaggregation of Revenue [Line Items]
Sales	19,874	19,820	40,092	40,925
Reportable Segments | U.S. Retail Pharmacy | Retail
Disaggregation of Revenue [Line Items]
Sales	7,703	7,847	14,689	14,774
Reportable Segments | International
Disaggregation of Revenue [Line Items]
Sales	5,651	5,563	10,840	11,381
Reportable Segments | International | Pharmacy
Disaggregation of Revenue [Line Items]
Sales	898	958	1,766	1,975
Reportable Segments | International | Retail
Disaggregation of Revenue [Line Items]
Sales	1,994	1,880	3,643	3,676
Reportable Segments | International | Wholesale
Disaggregation of Revenue [Line Items]
Sales	2,759	2,725	5,431	5,730
Reportable Segments | U.S. Healthcare
Disaggregation of Revenue [Line Items]
Sales	1,634	527	2,622	577
Corporate and Other
Disaggregation of Revenue [Line Items]
Sales	$ 0	$ (1)	$ 0	$ (1)

Related parties (Details)

Related parties (Details) - Affiliated Entity - AmerisourceBergen - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022	Aug. 31, 2022
Related Party Transaction [Line Items]
Purchases, net	$ 15,759	$ 15,063	$ 31,199	$ 30,854
Trade accounts payable, net of Trade accounts receivable	$ 7,839		$ 7,839		$ 6,915

Supplemental information - Narr

Supplemental information - Narrative (Details) - USD ($) shares in Millions, $ in Billions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022	Aug. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable from related party	$ 1.4		$ 1.4		$ 1.1
Accumulated depreciation and amortization on property, plant, and equipment	$ 12.8		$ 12.8		12.8
Antidilutive securities excluded from EPS calculations (in shares)	16	17.9	16.8	16.9
Incremental common shares attributable to dilutive effect of share-based payment arrangements			4.8
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables	$ 4.3		$ 4.3		$ 4

Supplemental information - Depr

Supplemental information - Depreciation and Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Supplemental Cash Flow Elements [Abstract]
Depreciation expense	$ 361	$ 348	$ 697	$ 683
Intangible assets amortization	199	175	357	340
Total depreciation and amortization expense	$ 559	$ 524	$ 1,055	$ 1,024

Supplemental information - Summ

Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Feb. 28, 2023	Aug. 31, 2022	Feb. 28, 2022	Aug. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Cash and cash equivalents	$ 1,088	$ 1,358
Marketable securities	752	1,114
Restricted cash	153	86
Cash, cash equivalents, marketable securities and restricted cash	$ 1,993	$ 2,558	$ 2,027	$ 1,270

Supplemental information - Sche

Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
	Nov. 24, 2021	Feb. 28, 2023	Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022	Nov. 23, 2021
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance		$ 157	$ 2,787	$ 1,042	$ 319
Recognition of acquisition of subsidiary		0	0	0	2,489
Acquisitions of non-controlling interests		0	(2,047)	0	(2,047)
Net loss attributable to Redeemable non-controlling interests		(1)	(12)	(24)	(33)
Redemption price adjustments		0	83	440	90
Reclassifications from redeemable non-controlling interests		0	0	(1,314)	0
Other		3	2	14	(6)
Ending balance		158	812	158	812
Conversion of Stock [Line Items]
Acquisitions of non-controlling interests		$ 0	(2,047)	$ 0	(2,047)
VillageMD
Increase (Decrease) in Temporary Equity [Roll Forward]
Acquisitions of non-controlling interests			1,900		1,900
Conversion of Stock [Line Items]
Acquisitions of non-controlling interests			$ 1,900		$ 1,900
Value of purchase tender offer	$ 1,900
Outstanding equity interest percentage	63%					30%
McKesson Corporation, GEHE Pharma Handel
Conversion of Stock [Line Items]
Outstanding equity interest percentage			30%		30%

Supplemental information - Su_2

Supplemental information - Summary of Dividends per Share (Details) - $ / shares	3 Months Ended				6 Months Ended
	Feb. 28, 2023	Nov. 30, 2022	Feb. 28, 2022	Nov. 30, 2021	Feb. 28, 2023	Feb. 28, 2022
Supplemental Cash Flow Elements [Abstract]
Cash dividends declared (in dollars per share)	$ 0.4800	$ 0.4800	$ 0.4775	$ 0.4775	$ 0.9600	$ 0.9550

Subsequent events (Details)

Subsequent events (Details) - USD ($) $ in Millions	Mar. 02, 2023	Feb. 28, 2023	Aug. 31, 2022
Subsequent Event [Line Items]
Total short-term debt		$ 4,222	$ 1,059
Subsequent Event | Unsecured Credit Facility, 364 Day Term, Due 2024 | Credit facilities
Subsequent Event [Line Items]
Total short-term debt	$ 900
Debt term	364 days